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Résumé 
Contexte Un objectif important de la prise en charge de l'arthrite juvénile oligoarticulaire 
serait d'altérer le cours de la maladie à l'aide d'une thérapie hâtive. Nous avons étudié l'effet 
des injections intra-articulaires de corticostéroïdes hâtives sur les chances d'atteindre un 
décompte d'articulation active de zéro et une maladie inactive.  
 
Méthode Les données démographiques, cliniques et thérapeutiques des patients avec 
oligoarthrite juvénile enrôlés dans une étude prospective longitudinale pancanadienne ont été 
collectées pendant 2 ans. Une injection hâtive était définie comme étant reçue dans les 3 
premiers mois suivant le diagnostic. Les équations d'estimation généralisées ont été utilisées 
pour l'analyse statistique.  
 
Résultats Trois cent dix patients ont été inclus. Cent onze (35.8%) ont reçu une injection 
hâtive. Ces derniers avaient une maladie plus active lors de l'entrée dans l'étude. Les patients 
exposés à une injection hâtive avaient une chance similaire d'obtenir un décompte 
d'articulation active de zéro, OR 1.52 (IC95% 0.68-3.37), p=0.306 mais étaient 
significativement moins à risque d'avoir une maladie inactive, OR 0.35 (IC95% 0.14-0.88), 
p=0.026.  
 
Interprétation Dans cette cohorte de 310 patients avec oligoarthrite juvénile, les injections 
hâtives de corticostéroïdes n'ont pas mené à une probabilité plus élevée d'atteindre un 
décompte d'articulation active de zéro ou une maladie inactive. Des problématiques 
méthodologiques intrinsèques à l'utilisation de données observationnelles pour fins 
d'estimation d'effets thérapeutiques auraient pu biaiser les résultats. Nous ne pouvons affirmer 
avec certitude que les injections hâtives n'améliorent pas le décours de la maladie. Des études 
prospectives adressant les limitations soulevées seront requises pour clarifier la question. 
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Mots-clés : Arthrite juvénile idiopathique, oligoarticulaire, injection intra-articulaire de 
corticostéroïdes, traitement hâtif, décompte d'articulation active de zéro, maladie inactive, 
pronostic. 
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Abstract 
Background One of the goals in oligoarticular juvenile idiopathic arthritis would be to alter 
the disease course with early therapy. We examined the association between early intra-
articular corticosteroid injections and the achievement of an active joint count of zero and 
inactive disease during the first two years after study enrollment.  
 
Methods We included oligoarticular juvenile idiopathic arthritis patients enrolled into a 
prospective longitudinal cohort across Canada. Demographic, clinical and treatment-related 
information were collected. Early intra-articular corticosteroid injections was defined as 
having received the first injection within 3 months of diagnosis. Generalized estimating 
equations were used for data analysis.  
 
Results A total of 310 patients were included, of whom 111 (35.8%) received an early 
injection. Participants who received an early injection had more severe disease at baseline. 
Patients exposed to early injections had a similar chance to achieve an active joint count of 
zero, OR 1.52 (95%CI 0.68-3.37), p=0.306 but were significantly less likely to achieve 
inactive disease, OR 0.35 (95%CI 0.14-0.88), p=0.026.  
 
Interpretation In this cohort of 310 oligoarticular juvenile idiopathic arthritis patients, early 
intra-articular corticosteroid injections did not result in an increased risk of achieving an active 
joint count of zero or inactive disease. Methodological issues encountered when estimating 
treatment effect using observational data might have biased the estimates obtained. Firm 
conclusion on the inefficacy of early injections in improving outcomes in this population 
cannot be drawn from this study. Prospective studies addressing the limitations raised will be 
needed to clarify if early injections can alter the disease course. 
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Chapter 1: Introduction 
1.1 Juvenile idiopathic arthritis   
Juvenile idiopathic arthritis (JIA) is the most frequent rheumatological disease in children (1).  
It is defined as arthritis of unknown etiology that begins before the 16th birthday and persists 
for a minimum of 6 weeks (2). In developped countries, the prevalence is estimated at 16-150 
cases per 100 000 children (3). The Canadian Pediatric Surveillance Program revealed that 
from 2007-2009, the annual incidence of JIA in Canada was 4.3 per 100 000 children (4). JIA 
is an umbrella term encompassing several distinct subtypes of childhood onset arthritis. The 
current classification, based on clinical features as well as autoantibody profile, consists of 7 
different subtypes: systemic-onset JIA, oligoarticular JIA (oligo-JIA), rheumatoid factor 
negative polyarticular JIA, rheumatoid factor positive polyarticular JIA, psoriatic arthritis, 
enthesitis related arthritis and undifferentiated arthritis. Oligo-JIA is the subtype most 
commonly encountered. 
 
The pathogenic steps leading to the development of JIA remain to be characterized. It likely 
results from an interplay of genetic predisposition, hormonal factors and diverse 
environmental exposures leading to dysregulation of the immune system. Genome-wide level 
of significance have been shown for diverse genetic loci, including HLA, PTPN22 and PTPN2 
(5, 6). The sex ratio difference seen for most JIA subtype and peak age of onset suggest that 
the hormonal system is part of the pathogenesis (7, 8). Infectious agents represent the main 
suspect among environmental factors, although no clear causal link has been established with 
one specific pathogen (9-12).  
 
1.2 Oligo-JIA 
The oligoarticular subtype represents 27-56% of JIA (3). It is characterized by involvement of 
≤ 4 joints during the first 6 months of disease. There are 5 exclusion criteria for this subtype 1) 
psoriasis or a history of psoriasis in the patient or a first-degree relative, 2) HLA B27 in a male 
whose arthritis started after the 6th birthday, 3) ankylosing spondylitis, enthesitis related 
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arthritis, sacroiliitis with inflammatory bowel disease, Reiter's syndrome or acute anterior 
uveitis or a history of one of these conditions in a first-degree relative, 4) positive IgM 
rheumatoid factor on 2 occasions at least 3 months apart and 5) systemic-onset JIA. The oligo-
JIA subtype is further characterized by the number of joints affected after the first 6 months of 
disease. The persistent course implies that no more than 4 joints are affected during the entire 
disease course. The extended course applies to those who develop arthritis in >4 joints after 
the initial 6 months of disease. The risk of progression to an extended course is higher in the 
first years following diagnosis. Involvement of the hand, wrist, cervical spine, ankle, 
symmetric disease, having 2-4 active joints, erythrocyte sedimentation rate (ESR) ≥ 20 
mm/hour and having a positive antinuclear antibody (ANA) in the first 6 months are factors 
that have been shown to be associated with an extended disease course (13, 14). This sub-
classification is not just semantic as long term prognosis seems less favorable in children with 
an extended course (15).  
 
Girls are more commonly affected than boys, with a 3:1 ratio in Caucasians. The peak age of 
onset is at 1-2 years old (1). Joints of the lower limbs are more frequently affected than those 
of the upper limbs or of the axial skeleton. Warmth, swelling, tenderness on palpation or pain 
with mobilisation are typical physical examination findings. The majority of patients are ANA 
positive (65-85%) (1). This autoantibody is especially prevalent in younger girls and in 
patients who have or will develop uveitis. The later is one of the only extra-articular 
manifestation seen in oligo-JIA.  
 
1.3 Disease course and prognosis of oligo-JIA patients 
Although often regarded as the subtype with the best prognosis, oligo-JIA is a chronic disease. 
A subset of patients will remain with prolonged active disease with ongoing need for systemic 
medications for years after diagnosis. A recent study comprising 416 Canadian children with 
oligo-JIA reported that only 7.6% achieved disease remission in the first 2 years following 
study entry (16). At 5 years, the proportion of patients in remission was 57.6%. The 
probability to be off medication was 15.5% and 80.7% at 1 and 5 years, respectively. Fantini 
et al. reported remission rates of 420 oligo-JIA patients attending one Italian center during a 
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median (range) observation period of 6.2 (0.5-35.0) years (17). One hundred and forty-two 
(33.8%) patients were in remission at the last study visit and 55 (13.1%) had been in remission 
at one point during the study but were not in remission at the last assessment. It is interesting 
to note that 223 (53.1%) oligo-JIA patients never achieved remission during the study period. 
In the Nordic Cohort Study, a prospective multicenter JIA cohort, 440 children with JIA were 
reassessed after a median (range) time of 98 (84-147) months following disease onset (18). 
The median (interquartile range- IQR) active joint count was 0 (0-0) and 0 (0-1) among the 
132 oligo-persistent and 78 oligo-extended JIA patients. Among the 126 oligo-persistent JIA 
patients for which information was available, 83 (65.9%) were in remission off medications, 4 
(3.1%) were in remission on medication and 39 (31.0%) were not in remission. As expected, 
proportions were different for the oligo-extended subgroup with 16 (21.3%), 12 (16.0%) and 
47 (62.7%) children who were in remission off medication, in remission on medication and 
not in remission, respectively. Another study reported remission data on 167 oligo-persistent 
and 91 oligo-extended JIA followed for a minimum of 4 years at 3 tertiary care pediatric 
rheumatology centers (19). Clinical remission on and off medication were found in 60% and 
68% of oligo-persistent patients and 81% and 31% of oligo-extended patients, respectively. 
The median (IQR) length of active disease before patients achieved the first episode of 
inactive disease was 17 (9-27) months for oligo-persistent and 22 (13-54) months for oligo-
extended JIA patients. Once the disease becomes inactive, the risk of disease flare remains, 
even after years of quiescence. A study of 224 patients with oligo-JIA reported that the median 
(range) time to flare after the disease was brought under control was 5.2 (2.1-13.4) years (20). 
These large studies highlight the fact that oligo-JIA must be considered a chronic disease. 
There is a definite need to optimize therapeutic management of these patients to allow more 
children to achieve and stay into prolonged remission. 
 
Anatomic damage, functional impairment, quality of life, educational and work status are 
other aspects that come into play for the prognosis of oligo-JIA patients. Radiologic 
abnormalities in the form of erosions, joint space narrowing and overgrowth were observed in 
25%, 14% and 25%, respectively in a study of 81 oligo-JIA patients who had radiographs 
done after a median (range) of 8.6 (2.3-24.1) years after disease onset (21). Other studies have 
reported erosions in 4-35% of patients (14, 22-24). Abnormal Health Assessment 
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Questionnaire scores were found in 22% and 47% of oligo-persistent and oligo-extended 
patients, respectively, after a median disease duration of 14.9 years (22). A large multinational 
cross-sectional study explored the health-related quality of life of 1539 children with oligo-JIA 
a few years after their diagnosis (25). Not surprisingly, patients of the oligo-persistent subtype 
faired better than the other JIA subtypes in all of the Child Health Questionnaire domains. The 
extended-oligo subtype had similar scores on all domains than polyarticular and systemic-
onset JIA. A study on 215 JIA patients from Germany of which 85 had oligo-JIA reported 
educational level and employment status after a median (range) follow up period of 16.5 (10-
30) years (26). In the entire cohort, the 20-35 year-old patients achieved a similar or higher 
educational level than the age-matched controls from the general population. Similarly, in a 
cohort of American oligo-JIA patients diagnosed in the 1990s and followed for at least 5 years 
after diagnosis, only 6% had school limitations (27). Although oligo-JIA patients have an 
overall favorable prognosis compared to their JIA counterparts, they remain at risk to develop 
anatomic damage, impaired functional status and quality of life. These aspects are not to be 
neglected and may also benefit from earlier and more aggressive disease control. 
 
  
 
Chapter 2: Use of intra-articular corticosteroid injections 
in oligo-JIA 
2.1 Recommendations for intra-articular corticosteroid injections in oligo-JIA 
Despite the fact that oligo-JIA is one of the most common rheumatic disease encountered by 
pediatric rheumatologists, few comparative studies are available to guide therapeutic choices. 
No prospective randomized control trials comparing the efficacy of different first-line agents 
have been conducted. In 2011, the American College of Rheumatology published treatment 
recommendations to help clinicians in therapeutic decision making (28). As general 
suggestions, intra-articular corticosteroid injections (IAS) were recommended to treat active 
arthritis regardless of the JIA subtype or intake of systemic medication. Authors also 
mentioned that when the benefits gained from IAS lasted at least 4 months, subsequent IAS 
should be considered to treat disease flares. For children with a shorter response to IAS, the 
addition of systemic medications should be considered. In patients with ≤4 active joints, the 
use of first-line nonsteroidal anti-inflammatory drugs (NSAIDs) monotherapy was suggested 
only for those with mildly active disease, without contractures or poor prognostic features. 
Methotrexate (MTX) was proposed as part of the first-line armentorium in those with highly 
active disease and poor prognostic features. For patients with a history of arthritis in 5 or more 
joints, MTX was suggested as part of the first-line therapy in patients with high disease 
activity or moderate disease activity associated with poor prognostic features. When a patient 
has only a few active joints, starting systemic therapy may not always be the best option as it 
implies committing to the intake of daily medication with potential side effects. Also, if a 
patient is already on a systemic agent, stepping up systemic therapy for 1-2 active joints may 
not be desirable. The use of IAS becomes an attractive option for these scenarios. 
 
2.2  Mechanisms of action of IAS 
Intra-articular corticosteroid injections to treat arthritis was reported for the first time in 1951 
(29). Different corticosteroid formulations may be utilized for intra-articular injections but 
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triamcinolone hexacetonide is most commonly used in pediatrics due to its superior efficacy 
(30-35). The mechanisms of action of locally injected corticosteroids are diverse (36). Once 
delivered into the cell, the corticosteroid binds to the cytosolic glucocorticoid receptor. This 
binding triggers genomic and non-genomic effects. The former results from alteration of gene 
transcription which will lead to down-regulation of pro-inflammatory mediators and up-
regulation of anti-inflammatory mediators expression. Non-genomic effects could potentially 
account for the rapidity of action of IAS. Diverse mechanisms have been proposed, such as 
alteration of the physicochemical properties of cellular membranes and binding of 
glucocorticoid to a membrane-bound receptor instead of a cytosolic one.   
 
2.3 Advantages and potential side effects of IAS 
An indisputable advantage of IAS over other anti-inflammatory or immunosuppressive 
therapies is its rapidity of action. As compared to many weeks to even a few months with 
NSAIDs and MTX, respectively, response to IAS is usually seen after a few days or weeks. It 
allows patients to redeem their physical functions more rapidly without the need to take 
regular systemic medications. As an example, improved gait pattern and increased muscle 
power were demonstrated in a group of children following lower limb IAS (37). The rapidity 
of action of IAS could also facilitate physiotherapy, a key component of JIA treatment. Rapid 
resolution of symptoms could also lower the frequency of local complications such as 
contractures, muscular atrophy and limb length discrepancy (38, 39). Another benefit of IAS is 
the possibility to wean off systemic therapies after the procedure. A study conducted mostly 
among children with JIA showed that 60.6% of patients were able to stop their systemic 
treatment after IAS (39). The proportion was even higher in children with oligo-JIA (74%).  
 
Intra-articular corticosteroid injections have a favorable adverse effect profile. Side effects 
resulting from IAS are mainly local. Skin atrophy and depigmentation are one of the most 
commonly encountered local side effects (40, 41). It is presumed to be secondary to leakage of 
the corticosteroid within the subcutaneous tissues. Smaller joints are more at risk. The atrophic 
skin changes will often improve and may even resolve over time. Intra-articular and peri-
articular calcifications may also be seen (42). They are often asymptomatic and only identified 
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on radiographs. Acute crystal synovitis has been described and should resolve by itself after a 
few days (39, 43). Septic arthritis is always a potential threat but it remains extremely rare.  
Cartilage damage does not seem to occur following IAS in children (44, 45). Systemic side 
effects have also been reported but are felt to be uncommon. Transient suppression of the 
hypothalamic-pituitary-adrenal axis, altered glucose metabolism and anaphylaxis are among 
the systemic effects described (46-48).  
 
2.4 Factors influencing IAS efficacy 
Specific patient characteristics or elements related to the IAS procedure have been shown to 
affect the odds of response to the injection. Less favorable response have been described when 
the joints injected are elbows or ankles (49, 50). Injections done under radiological guidance 
may offer a benefit as placement of the needle in the intra-articular space can be confirmed 
(51). Contradictory results were obtained when examining the impact of gender, JIA subtype, 
disease duration, concomitant intake of systemic medications, ANA status and the presence of 
an inflammatory profile on the probability and/or duration of a positive response to IAS (30, 
32, 34, 49, 51-56). The important heterogenicity in the methodology and patient population 
included in these studies may explain in part these contradictory results. Identification of 
biomarkers that could inform on the chance of success of IAS would be helpful in prioritizing 
therapies. Foell et al. explored the relationship between serum or intra-articular concentration 
of protein S100A2 and response to IAS in 22 patients with oligo-JIA (57). Non-responders 
had significantly higher levels of the protein in the serum prior to injection. Moreover, serum 
levels were increasing in non-responders as opposed to decreasing in responders. Another 
study suggested that the percentage of neutrophils in synovial fluid was a predictor of duration 
of response to IAS (34). Longer response time was seen in children with < 20% neutrophils. 
Other biomarkers such as gamma delta (γ/δ+) and B CD5+ lymphocytes in the synovial fluid 
were not helpful in predicting the response to IAS (55). 
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2.5 Utilization and efficacy of IAS in oligo-JIA 
Various rates of IAS have been reported in JIA patients (32% to >90%) (14, 20, 27). 
Contemporary data from the Research in Arthritis in Canadian Children Emphasizing 
Outcomes (ReACCh Out) cohort reported that 43% of oligo-JIA had received at least one IAS 
in the first 6 months following study entry (58). The wide range seen in the literature may be 
partly explained by the different follow up time of these studies but also from the absence of 
evidence-based data on the optimal use of IAS in oligo-JIA. Also, easily accessible joints like 
knees, ankles and wrists are often injected by the rheumatologist and do not require a specific 
set-up such as that required for deep seated or less accessible joints (59).  For those, patients 
are often referred to an orthopedic surgeon or an interventional radiologist to allow the 
injection to be done under radiological guidance.  
 
Studies assessing the efficacy of IAS in oligo-JIA patients are difficult to compare as the study 
setting and patient population are not homogeneous (Table I). Key elements that allow proper 
interpretation of these studies such as the JIA classification, number of IAS received, 
concomitant use of systemic therapy, the definition of response to IAS and of a flare and 
duration of follow up after the IAS vary or are not always even mentioned. Studies reporting 
response rates specific to the oligo-JIA subgroup have found favorable responses in 43-100% 
of children within the first year following IAS (31, 39, 44, 52, 60, 61). The data on the 
efficacy of re-injections is scant and none targets specifically oligo-JIA patients (30, 52, 53). 
No clear trend is seen in the re-injection studies as some report similar success rate and others 
show a lower efficacy. Most importantly, no studies have yet addressed the impact of early 
IAS on disease activity over time. 
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Table I.  Efficacy of IAS in juvenile idiopathic arthritis patients 
 Study design Oligo-JIA / JIA, N 
Girls,  
% 
Corticosteroid 
formulation 
used  
Concomitant 
systemic 
treatment, % a 
Disease 
duration, 
years 
Follow up time 
post IAS, months 
Favorable 
response, % 
Duration of 
response, months  
Allen et al. 
(52) 
Prospective, 
multicentric 29/29 90 TH 100 4.2 ± 4.0 
6.0  68 
n/a  12.0 50 
24.0  17 
Beukelman 
et al. (62) 
Retrospective, 
unicentric 16/38 87 TA, TH 37
 b n/a ≤ 3.3 44 n/a 
Bloom et al. 
(30) 
Retrospective, 
multicentric 37/61 74 TA, TH, MP 97 
2.8 
(0.1-13.0) c 
0.3 100 
12.5 (0.5-44.0) c  12.0 52 
24.0 20 
36.0 7 
Breit et al. 
(53) 
Retrospective, 
unicentric 
 
83/83 
Early onset 
pauci 
72 
TH 
100 
2.7 ± 2.3  
(ANA-) 
3.0 ± 2.6  
(ANA+) 
16.0 ± 5.9  n/a  
30.3 d 
38/38 
Late onset 
pauci 
45 100 
2.9 ± 2.3  
(HLA B27-) 
2.4 ± 1.9 
(HLA B27+) 
11.8 d 
 
de Oliveira 
Sato et al. 
(63) 
 
Retrospective 64/77 66 TA, TH 100 n/a 51.6 (32.4-73.2) e 57 n/a 
Eberhard et 
al. (32) 
Retrospective, 
unicentric 
90/124 79 TH 
n/a 
3.1 ± 3.4 
≥15.0 
 
n/a 
 
9.1 ± 3.5 
 
89/119 
 
81 TA 3.3 ± 3.3 6.8 ± 3.4 
 
Hertzberger
-ten Cate et 
al. (60) 
 
Retrospective, 
unicentric 21/21 n/a TA n/a n/a ≥6.0 100 15.2 (1.0-40.0) 
c 
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Table I.  Efficacy of IAS in juvenile idiopathic arthritis patients (continued) 
 Study design Oligo-JIA / JIA, N 
Girls, 
% 
Corticosteroid 
formulation 
used 
Concomitant 
systemic 
treatment, % a 
Disease 
duration, 
years 
Follow up time 
post IAS, months 
Favorable 
response, % 
Duration of 
response, months 
 
Huppertz et al. 
(44) 
 
Unicentric 9/9 n/a TH 100 n/a 
1.8 89 
n/a 
13.0 86 
Laurell et al. 
(64) 
Prospective, 
unicentric 19/30 70 TA 87 2.0 (0.5-13.9) 1.0 72 6.0 (4.0-11.0)  
Lepore et al. 
(55) Unicentric 35/37 81 TH 
None were on 
NSAIDs f n/a 41.8 (26.0-69.0) 
c 33 13.9 (0-54.0) c 
Marti et al. (54) Retrospective, unicentric 37/60 70 TA, TH 82 n/a 28.0 (1.0-69.0) 51 23.1 (0-69.0) 
Miotto E Silva 
et al. (51) Retrospective 48/88 75 n/a n/a n/a 84.0 ± 48.0 70 
 
18.1 ± 13.0 
 
Neidel et al. 
(65) 
Prospective, 
unicentric 18/48 63 TH 100 2.0 (0.1-16.0) 26.4 (24.0-81.6)
  76 n/a 
Padeh and 
Passwell (39) Unicentric 43/43 66 TH n/a n/a 6.0 82 n/a 
Papadopoulou 
et al. (66) 
Retrospective, 
unicentric 109/220 80 TH, MP 62 0.6 (0.2-2.5) 
e 
12.0 50 
n/a 24.0 32 
36.0 20 
Ravelli et al. 
(56) 
Prospective, 
unicentric 81/94 71 TH 82 
2.9 ± 3.2 g 
4.2 ± 3.9 h 6.0 69 n/a 
Remedios et al. 
(67) Prospective 7/11 64 TH n/a 5.4 ± 3.0 ≤16.0 63 14.0 (12.5-16.0) 
Tynjälä et al. 
(68) 
Retrospective, 
unicentric 15/32 63 
 
Ankles/feet 
MP 
 
Hips 
TH 
 
69 
4.3 (0.5-8.1) 
Ankles/feet 
 
1.1 (0.5-10.9) 
Hips 
3.0 64 3.5 (0.5-12.0) 
Ankles/feet 
 
11.5 d 
Hips 
6.0 55 
12.0 40 
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Table I.  Efficacy of IAS in juvenile idiopathic arthritis patients (continued) 
 
 
 
 
 
 
 
 
 
 
Data showed as mean ± standard deviation or median (range), unless otherwise specified; a NSAIDs and/or disease-modifying antirheumatic drug; b Proportion 
taking NSAIDs not mentioned; c Mean (range); d Median; e Median (IQR); f No mention of other systemic therapies; g Patients who were in sustained 
remission at 6 months; h Patients who had recurrence of arthritis at 6 months; i Proportion of remission in oligo-JIA patients; IAS: intra-articular corticosteroid 
injection; MP: methylprednisolone; N: number; n/a: not available; NSAIDs: nonsteroidal anti-inflammatory drugs; Pauci: pauciarticular; TA: triamcinolone 
acetonide; TH: triamcinolone hexacetonide. 
 Study design Oligo-JIA / JIA, N 
Girls, 
% 
Corticosteroid 
formulation 
used 
Concomitant 
systemic 
treatment, % 
Disease 
duration, 
years 
Follow up time 
post IAS, months 
Favorable 
response, % 
Duration of 
response, months  
Ünsal et 
al. (61) 
Retrospective, 
unicentric 17/37 41 TA n/a 4.7 ± 2.9 
6.0 81i 
n/a 
12.0 69 i 
Zulian 
et al. 
(69) 
Prospective, 
unicentric 85/85 78 TA, TH n/a 
3.6 ± 3.7 
(TH) 
2.7 ± 2.9 
(TA) 
6.0 81 (TH) 53 (TA) 
n/a  12.0 67 (TH) 43 (TA) 
24.0 60 (TH) 33 (TA) 
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2.6 Early disease control and its impact on the disease course 
One of the ultimate goals in JIA management would be to alter the course of the disease with 
early therapy. Not only would patients benefit in the short term from faster disease control but 
it could translate into longer term benefit by decreasing the occurrence of damage. Early 
disease control might also impact on the immunological behavior of JIA and alter the long 
term disease course, a concept called the "window of opportunity". This notion also applies to 
other conditions related to JIA, namely rheumatoid arthritis (RA) (62). Transformation of an 
acute self-resolving inflammatory process into a chronic one is a complex, multi-step process.  
It implies chemokines that will keep effector cells within the joints as well as up-regulation of 
anti-apoptotic signals preventing death of effector cells. The cytokine profile in synovial fluid 
of RA patients in the early disease phase has been found to differ from the profile seen in 
established disease (63). It seems plausible that early therapeutic intervention during this 
window period could modulate the immune system response and alter the long term disease 
course. A recent meta-analysis supports this concept in RA (64). Studies considered for this 
report were those in which at least one disease-modifying antirheumatic drug (DMARD) was 
started within the first 2 years after onset of symptoms and for which time from onset of 
symptoms to start of therapy was assessed as a potential predictor. This study showed that 
duration of symptoms before starting therapy was associated with sustained remission 
following complete withdrawal of DMARDs. Each additional week of symptoms without 
DMARDs therapy decreased the risk of a prolonged remission with a hazard ratio of 0.98 
(95% confidence interval (95%CI) 0.98-0.99; p< 0.001).   
 
Very few studies have addressed the efficacy and impact of early aggressive therapy in 
recently diagnosed JIA. Even after expanding to RA studies, the data remains scant when early 
IAS is the intervention of interest. Early IAS (≤2 months from JIA diagnosis) was shown to 
lower the frequency of leg length discrepancy in 30 children with oligo-JIA but unfortunately, 
no data on the effect of early IAS on disease activity was available in that study (38). A 
recently published sub-analysis of the "Behandel Strategieën" (BeSt) study compared the 
disease course over 8 years among 508 early RA (diagnosis <2 years) patients who received 
(N=60) or not (N=448) an IAS within 1 year of study enrollment (65). Rheumatoid arthritis 
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patients who were injected had higher Disease Activity Score in 44 joints and Health 
Assessment Questionnaire score during the first year of the study, although the differences 
were less than the minimal clinically significant difference. No significant differences in the 
Disease Activity Score in 44 joints and Health Assessment Questionnaire were found 
afterwards, up to 8 years after enrollment. The systemic treatment steps provided were also 
similar between both groups. A retrospective study evaluated the efficacy of multiple IAS 
performed after a median (IQR) of 0.6 (0.2-2.5) years after diagnosis in 220 Italian JIA 
patients, of whom 109 had oligo-JIA (66). At the time of IAS, 61.8% were taking systemic 
therapies. Synovitis flare was defined as a flare of arthritis in injected but also in uninjected 
joints, as the therapeutic steps provided to treat the active uninjected joints could have 
contributed to the persistence of remission in the injected joints. Survival without synovitis 
flare was 50.0%, 31.5% and 19.5% at 1, 2 and 3 years after the IAS, respectively. This study 
had no control group (i.e. systemic therapy without IAS) thus the effect of mutiple IAS per se 
cannot be isolated. Additionally, although the median disease duration was short, not all 
patients were injected shortly after JIA diagnosis. Interestingly, the number of joints that 
flared (n=309) was less than half of the number of injected joints (n=725). This may suggest 
that following IAS, less aggressive therapy might be needed to treat disease flares, but again, 
the absence of a control group precludes definitive conclusions.  
 
Studies of JIA patients have focused on early aggressive systemic therapy and not on early 
IAS as a potential factor influencing disease activity over time. In the Trial of Early 
Aggressive Therapy in Polyarticular Juvenile Idiopathic Arthritis (TREAT), 85 patients with a 
recent diagnosis (<12 months) of polyarticular JIA and naive to biologics were randomized to 
one of 2 treatment group: MTX, etanercept and prednisolone (aggressive treatment arm) or 
MTX, placebo etanercept and placebo prednisolone (conventional treatment arm) (67). 
Patients randomized to the aggressive arm were more likely to achieve clinical inactive 
disease at 6 months (40% vs. 23%; p=0.08) and clinical remission on medication at 12 months 
(21% vs. 7%; p=0.05), although findings were not statistically significant. Interestingly, the 
only predictor of clinical inactive disease at 6 months was disease duration at enrollment: for 
each month gained on therapy after disease onset, the odds of achieving clinical inactive 
disease were 1.32 greater (p<0.011). The Aggressive Combination Drug Therapy in Very 
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Early Polyarticular JIA trial was a randomized, open label multicentric trial enrolling patients 
within 6 months of JIA diagnosis with at least 5 active joints and who were naive to DMARDs 
(68). Patients were treated with either MTX alone (N=20), COMBO therapy (MTX, 
hydroxychloroquine and sulfasalazine; N=20) and MTX and infliximab (N=19). At 54 weeks, 
inactive disease was achieved by 25%, 40% and 68% of the MTX alone, COMBO and MTX-
infliximab groups, respectively (p=0.002). Also, the mean time spent in inactive disease was 
longest in the MTX-infliximab arm (26 weeks) when compared to the COMBO (13 weeks) 
and MTX (6 weeks) arms (p=0.001). No similar studies focusing on oligo-JIA are available. 
Moreover, no long term data is yet available in participants of JIA trials who were provided 
with early aggressive therapy. The impact of early disease control on the long term risk of 
achieving sustained complete remission still needs to be determined. Only then will the 
concept of a window of opportunity in JIA will be better understood. 
 
Although our study was not designed to address the existence of a window of opportunity in 
oligo-JIA, this concept motivated the search for an effective and acceptable therapeutic option 
that could be given early following JIA diagnosis and would at least, improve short term 
outcomes. Long term studies could subsequently address if the therapeutic intervention could 
modify the disease biology and trajectory over the long term. Due to their efficacy and overall 
acceptance among both pediatric rheumatologist and patients/parents, IAS are a potential 
therapeutic candidate for this task. 
 
2.7 Objectives and hypotheses 
The primary aim of this study was to examine the association between early IAS and the 
achievement of an active joint count of zero during the first 2 years after study enrollment. We 
hypothesized that patients who received an early IAS would be more likely to achieve an 
active joint count of zero.  
 
The secondary aim was to analyze the effect of early IAS on the achievement of inactive 
disease during the first 2 years after study enrollment. We hypothesized that inactive disease 
would be found more frequently in patients who received an early IAS. 
  
 
Chapter 3: Methodology 
3.1 Study population 
Patients included in this study were enrolled into the ReACCh Out study, a prospective 
longitudinal cohort established to study JIA outcomes. A detailed description of the design and 
methods of the study has been published previously (69). Briefly, ReACCh Out was a 
prospective multicenter cohort study conducted in 16 pediatric rheumatology centers across 
Canada (14 academic and 2 community centers). Patients were eligible to take part in that 
study if they were diagnosed with JIA within the past 12 months, according to the 
International League Against Rheumatism criteria (2). Participants were followed every 6 
months during the first 2 years and then yearly up to 5 years. Demographic, clinical and 
medication data were collected prospectively on standardized forms at each study visit. 
Medication changes were recorded at interim visits. This current analysis was undertaken 
using a subset of patients (oligo-JIA) enrolled in the ReACCh Out cohort study. 
 
3.2 Inclusion and exclusion criteria 
Included in this study were all patients with a diagnosis of oligo-JIA, (as defined by the 
subtype diagnosed at the 6-month visit and confirmed at the 24-month study visit) and those 
for whom all first 5 visits were completed (baseline, 6-month, 12-month, 18-month and 24-
month visit). Patients who received their first IAS before enrollment were excluded.  
 
3.3 Data collection 
Eligible participants were identified in the central ReACCh Out database. Data extraction was 
performed on March 11th 2012. After the completion of the 24-month study visit, a 6 months 
lag was allowed for data to be entered in the main database. It was expected that patients 
enrolled before September 11th 2009 would have all data entered by the time of data 
extraction. Patients missing one or more study visits were excluded. Data included in this 
report comprise that from enrollment up to the 24-month study visit.  
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Demographic, clinical and treatment-related information were collected. Data collection in 
ReACCh Out was performed using standardized forms and questionnaires filled by the 
physician and the patient or parents (see appendix A). The Childhood Health Assessment 
Questionnaire (CHAQ), in which 0 indicates the best and 3 the worst function, was used as a 
measure of physical function (70, 71). The physician global assessment of disease activity 
(PGADA) and the patient global assessment of overall well-being (Patient Global) were also 
collected. Both are 10-cm visual analog scales in which 10 cm indicates higher disease activity 
with respect to the physician and patient's perspective, respectively.  
 
3.4 Definitions of exposure 
Exposure to IAS was defined as follows: early IAS, if the first IAS was performed ≤ 3 months 
after JIA diagnosis and no early IAS, if no IAS was performed during that time period. A 
minimum consecutive period of medication exposure had to occur for a participant to be 
labelled as having been exposed to a systemic medication. Each agent had its specific 
predetermined exposure time: ≥1 month for corticosteroids, ≥2 months for NSAIDs, ≥3 
months for MTX, leflunomide, hydroxychloroquine or sulfasalazine and ≥4 months for 
biologics. These minimal exposure times were used to ensure a patient would not be labelled 
exposed to a medication when he did not receive it long enough to benefit from it. Early 
exposure to DMARDs was defined as exposure to MTX, leflunomide, hydroxychloroquine, 
sulfasalazine and/or biologics in the 6 months following study enrollment. 
 
3.5 Outcomes  
The primary outcome was an active joint count of zero, as determined by the treating 
rheumatologist during physical examination. The active joint count was treated as a 
categorical variable (active joint count of zero: yes/no). The secondary outcome was inactive 
disease, derived from the Wallace criteria (72). The Wallace criteria were created in 2003 to 
help bring homogenicity in the definition of inactive disease used in JIA trials. The state of 
inactive disease was reached if the following 4 criteria were met for 6 consecutive months (2 
consecutive visits), regardless of medication intake: (1) no joints with active arthritis, (2) no 
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fever, rash, serositis, splenomegaly or generalized lymphadenopathy attributable to JIA, (3) no 
active uveitis, and (4) PGADA indicates no disease activity. The fifth item, normal ESR or C-
reactive protein (CRP) was not included in the definition of inactive disease. Of note, the 
definition of inactive disease used for this study did not take into account the medication 
intake; a patient could have inactive disease while on medication.  
 
3.6 Repeated measurements: advantages and statistical considerations 
Our current project used data from a prospective longitudinal cohort study which generated 
repeated measurements over time. Each participant was seen on 5 occasions and at each visit, 
the same data was collected. These 5 visits took place at predetermined moments and were not 
dictated by the patient's clinical status. Longitudinal data offers many advantages one of which 
being the ability to obtain information on the outcome's trajectory over time. Per example, 
when assessing the effect of treatment A and B on the level of disease activity, the proportion 
of patients with inactive disease at 24 months may be similar between both groups, but the 
trajectory of disease activity over time may differ. Patients who received treatment A may 
have achieved and stayed in remission as soon as the second month of the study as compared 
to group B who only achieved remission at 18 months. This dynamic information allows to 
better characterize the effect of one or many independent variables on a dependent variable, 
taking into consideration the change over time.  
 
Statistical analysis of repeated measurements requires specific considerations. Measurements 
taken on the same subject over time might be correlated. Overlooking the within-patient 
correlation might lead to type I or type II errors (73). Assumptions underlying more traditional 
statistical analysis methods may not be fulfilled and using these methods might lead to biased 
results. Many statistical methods can assist in the analysis of repeated measurements. We 
chose the generalized estimating equation method (GEE). The GEE models the population 
mean of the outcome variable at each time point; this will generate information about the 
trajectory of the outcome variable at a population level. Visits made at predetermined time 
points as seen in our study are an ideal scenario for GEE (74). When visits are dictated by the 
clinical status of participants, using GEE may lead to biased results. GEE can handle missing 
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data but the missingness mechanism should not be missing at random (MAR) or missing not at 
random (MNAR) (75). Analyzing a dataset in which missing data are MAR or MNAR may 
lead to erroneous conclusions.  
 
3.7 Statistical analysis 
3.7.1 Descriptive statistics 
Patient characteristics at study enrollment were described using frequency (percentages; 95% 
confidence interval) for categorical variables, mean (standard deviation) for normally 
distributed continuous data and median (IQR) for non-normally distributed continuous data. 
Normality of data distribution was determined using the Kolmogorov-Smirnov test.  Baseline 
characteristics were compared between groups based on their exposure status to IAS.  
Comparisons were made using the chi-square or Fisher's exact test for categorical variables, 
the independent t test for normally distributed continuous variables and the Mann-Whitney U 
test for non-normally distributed continuous variables. 
 
3.7.2 GEE analysis 
GEE was used for the analysis of our primary and secondary objectives. The logistic binary 
model was selected since our dependent variables are both binary categorical variables. The 
use of GEE requires specification of the working correlation matrix, which reflects the 
correlation present among observations measured on the same subjects on repeated occasions 
(in our case the outcome).  Many types of working correlation matrices exist. For the current 
study, the working correlation matrix associated with the lowest "quasi-likelihood under the 
independence model criterion" was selected (76). The following working correlation matrices 
were assessed: first-order autoregressive, exchangeable, M-dependent and unstructured. The 
independent working correlation matrix was not tested as it assumed that the repeated 
measurements were uncorrelated which was not the case for our data. For the primary 
outcome, the M-dependent, where m=3, was chosen. This correlation matrix assumed that 
consecutive measurements have a common correlation coefficient, measurements taken 2 time 
 19 
periods away have a different correlation coefficient, etc. up to m-1 time periods; 
measurements separated by a time period greater than m-1 are assumed to be non-correlated. 
A first-order autoregressive working correlation matrix was selected for the secondary 
outcome. It assumed that the correlation between the measurements decreased with increasing 
interval of time between measurements. The robust estimator was chosen for the covariance 
matrix. This allowed to obtain valid estimates even if the working correlation matrix was not 
correctly specified, assuming that the sample size was large enough, which was the case in our 
study (N=310) (73). 
 
We first explored the effect of exposure to early IAS and other important patient 
characteristics on the risk of achieving an active joint count of zero and inactive disease with 
univariate analyses. Variables with a p value <0.10 were considered for the multivariate 
model. Early IAS was forced into the model because this was our covariate of interest. Being 
on NSAIDs at enrollment and early exposure to DMARDs were also included as these 
variables were considered clinically relevant. In addition, covariate adjustment for statistical 
models included all empirical confounders for the association between early IAS and the 
outcome. We used a conservative 8% change-in-estimate rule to identify empirical 
confounders suitable for inclusion in the model. The following 7 variables were considered to 
be potential confounders and were tested as described above: oligo-JIA course, active joint 
count of zero at enrollment, early exposure to DMARDs, on NSAIDs at enrollment, baseline 
CHAQ, PGADA and Patient Global. In the event that 2 independent variables were strongly 
correlated (Pearson's or Spearman's coefficient ≥0.6 and p value <0.05), only one was chosen 
for the multivariate analysis. The choice was based on both the clinical and statistical 
significance of the covariates. Interaction between exposure to early IAS and time since 
enrollment was examined. This allowed to assess if early IAS was associated with the change 
in the outcome over time. Our specific research interest was to explore the association between 
early IAS and the outcomes active joint count of zero and inactive disease rather than to derive 
an explanatory model for the primary and secondary outcomes. It was extremely important to 
minimize confounding by including all potential confounding variables. Therefore, we elected 
to enter the selected independent variables in the GEE multivariate model without performing 
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stepwise regression analysis. A p value < 0.05 for the variable early IAS and the interaction 
term was considered statistically significant. 
 
A first analysis was performed using all available data (complete cases analysis). We also 
performed multiple imputation (see section 3.8 Handling of missing data for details). Results 
of both the complete case analysis and the analysis using the imputed dataset are presented. 
Data analysis was performed using IBM SPSS Statistics Version 21.0. (Armonk, NY: IBM 
Corp.). 
 
3.8 Handling of missing data 
Missing data is not an uncommon issue encountered in prospective multicentric observational 
studies. Sites from which participants' data was missing were contacted to obtain the missing 
information, if available. This allowed to decrease significantly the amount of missing data. 
Unfortunately, certain data were truly missing hence it could not be retrieved. The proportion 
of missing data for the outcome measures and the independent variables were described. 
Baseline demographics of participants with and without a complete dataset were compared to 
assess if these 2 subset of patients differed significantly. Additionally, we explored if having a 
complete dataset was associated with the primary or secondary outcomes using univariate 
GEE logistic regression. Lastly, we assessed the missingness mechanism of variables having 
missing items. This was done by exploring if the outcomes and independent variables in the 
dataset were associated with the missing status of each variable having missing items. Due to 
the multiplicity of comparisons (136) performed for this task, Bonferroni correction was 
applied and only p values < 0.001 were considered statistically significant. If no statistically 
significant association was found, the missingness mechanism for that variable was presumed 
to be missing completely at random (MCAR). On the other hand, if a significant association 
was found with at least one variable, the missingness mechanism was assumed to be at least 
that of MAR. 
 
We performed multiple imputation for all 8 variables with missing items: the secondary 
outcome inactive disease, duration of symptoms at diagnosis, oligo-JIA course, ANA status, 
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early exposure to DMARDs, being on NSAIDs at enrollment, baseline CHAQ and baseline 
Patient Global. The following variables were used as predictors in the imputation model: 
gender, age at diagnosis, duration of symptoms at diagnosis, disease duration at enrollment, 
center, oligo-JIA course, ANA status, exposure to early IAS, early exposure to DMARDs, 
being on NSAIDs at enrollment, baseline CHAQ, baseline PGADA, baseline Patient Global, 
active joint count of zero (at each study visit) and inactive disease (at each study visit). The 
Markov Chain Monte Carlo modelling method was utilized (77). The number of iterations was 
set at 200 and 10 imputed datasets were created (78). The multiple imputation procedure was 
done using IBM SPSS Statistics Version 21.0. (Armonk, NY: IBM Corp.).  
  
3.9 Ethics approval 
The study was approved by the research ethics board at each institution and carried out in 
conformity with the declaration of Helsinki. 
 
  
 
Chapter 4: Manuscript and results 
4.1 Manuscript 
Please refer to the manuscript entitled: Do Early Intra-Articular Corticosteroid Injections 
Improve Outcome in Oligoarticular Juvenile Idiopathic Arthritis: The ReACCh Out Study. 
The manuscript is formatted for submission in Arthritis and Rheumatology as a full-length 
article. 
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Abstract 
 
Objectives One of the goals in oligoarticular juvenile idiopathic arthritis would be to alter the 
disease course with early therapy. We examined the association between early intra-articular 
corticosteroid injections and the achievement of an active joint count of zero and inactive 
disease during the first two years after study enrollment.  
 
Methods Included were oligoarticular juvenile idiopathic arthritis patients enrolled into a 
prospective longitudinal cohort across Canada. Demographic, clinical and treatment-related 
information were collected. Early intra-articular corticosteroid injection was defined as having 
received the first injection within 3 months of diagnosis. Generalized estimating equations 
were used for data analysis.  
 
Results A total of 310 patients were included, of whom 111 (35.8%) received an early 
injection. Participants who received an early injection had more severe disease at baseline. 
Patients exposed to early injections had a similar chance to achieve an active joint count of 
zero, OR 1.52 (95%CI 0.68-3.37), p=0.306 but were significantly less likely to achieve 
inactive disease, OR 0.35 (95%CI 0.14-0.88), p=0.026.  
 
Conclusion In this cohort of 310 oligoarticular juvenile idiopathic arthritis patients, early 
intra-articular corticosteroid injections did not result in an increased risk of achieving an active 
joint count of zero or inactive disease. Methodological issues encountered when estimating 
treatment effect using observational data might have biased the estimates obtained. Firm 
conclusion on the inefficacy of early IAS in improving outcomes in this population cannot be 
drawn from this study. Prospective studies addressing the limitations raised will be needed to 
clarify if early injections can alter the disease course. 
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Introduction 
Oligoarticular juvenile idiopathic arthritis (oligo-JIA) is one of the most commonly 
encountered rheumatological diseases in childhood. Although it is often regarded as the 
subtype with the best prognosis, studies have reported remission rates off medications varying 
from 21-68% four to eight years after diagnosis (1, 2). Importantly, the risk of disease flare 
remains present even after years of quiescence (3). Oligo-JIA must thus be considered a 
chronic disease.   
 
One of the ultimate goals in JIA management would be to alter the course of the disease with 
early therapy. Not only would patients benefit in the short term from faster disease control but 
it could translate into longer term benefit by decreasing the occurrence of damage. Early 
disease control might also impact on the immunological behavior of JIA and alter the long 
term disease course, a concept called the "window of opportunity". This notion also applies to 
other conditions related to JIA, namely rheumatoid arthritis (RA) (4). Interestingly, a shorter 
duration of symptoms before onset of therapy was associated with sustained RA remission 
following complete withdrawal of disease-modifying antirheumatic drugs (DMARDs). In the 
Trial of Early Aggressive Therapy in Polyarticular Juvenile Idiopathic Arthritis (TREAT), the 
only predictor of inactive disease at 6 months was disease duration at enrollment: for each 
month gained on therapy after disease onset, the odds of achieving inactive disease were 1.32 
greater (p<0.011). No similar studies focusing on the oligo-JIA population are available.  
 
The concept of a potential window of opportunity motivates the search for an effective 
therapeutic option that could be given early following JIA diagnosis and would improve 
outcomes. Due to their efficacy and overall acceptance among both pediatric rheumatologists 
and patients/parents, intra-articular corticosteroid injections (IAS) are a potential therapeutic 
candidate for this task. 
 
The primary aim of this study was to examine the association between early IAS and the 
achievement of an active joint count of zero during the first two years after study enrollment. 
The secondary aim was to analyze the effect of early IAS on the achievement of inactive 
disease. 
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Methods 
Study population 
Patients included in this study were enrolled into the Research in Arthritis in Canadian 
Children Emphasizing Outcomes (ReACCh Out) study, a prospective longitudinal cohort 
established to study JIA outcomes. A detailed description of the design and methods of the 
study has been published previously (5). Briefly, ReACCh Out was a prospective multicenter 
cohort study conducted in 16 pediatric rheumatology centers across Canada (14 academic and 
2 community centers). Patients were eligible to take part in ReACCh Out if they were 
diagnosed with JIA within the past 12 months, according to the International League Against 
Rheumatism criteria (6). Participants were followed every 6 months during the first 2 years 
and then yearly up to 5 years. Demographic, clinical and medication data were collected 
prospectively on standardized forms at each study visit. Medication changes were also 
recorded at interim visits. This current analysis was undertaken in a subset of patients (the 
oligo-JIA subtype) enrolled in the ReACCh Out cohort study.  
 
Inclusion and exclusion criteria 
Included in this study were all patients with a diagnosis of oligo-JIA (as defined by the 
subtype of JIA diagnosed at the 6-month visit and confirmed at the 24-month study visit) and 
those for whom all first 5 study visits were completed. Patients who received their first IAS 
before enrollment were excluded.  
 
Data collection 
Eligible participants were identified in the central ReACCh Out database. Data extraction was 
performed on March 11th 2012. Demographic, clinical and treatment-related information were 
collected. The Childhood Health Assessment Questionnaire (CHAQ), in which 0 indicates the 
best and 3 the worst function, was used as a measure of physical function (7, 8). The physician 
global assessment of disease activity (PGADA) and the patient global assessment of overall 
well-being (Patient Global) were also collected. Both are 10-cm visual analog scales in which 
10 cm indicates higher disease activity. Data included in this report comprise that from 
enrollment up to the 24-month study visit.  
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Definitions of exposure 
Exposure to IAS was defined as follows: early IAS, if the first IAS was performed ≤3 months 
of JIA diagnosis and no early IAS, if no IAS was performed during that time period. A 
minimum consecutive period of medication exposure had to occur for a participant to be 
labelled as having been exposed to a systemic medication. Each agent had its specific 
exposure time: ≥1 month for corticosteroids, ≥2 months for nonsteroidal anti-inflammatory 
drugs (NSAIDs), ≥3 months for MTX, leflunomide, hydroxychloroquine or sulfasalazine and 
≥4 months for biologics. These minimal exposure times were used to ensure a patient would 
not be labelled exposed to a medication when he did not receive it long enough to benefit from 
it. Early exposure to DMARDs was defined as exposure to MTX, leflunomide, 
hydroxychloroquine, sulfasalazine and/or biologics in the 6 months following study 
enrollment.  
 
Outcomes  
The primary outcome was an active joint count of zero, as determined by the treating 
rheumatologist during physical examination. The secondary outcome was inactive disease, 
derived from the Wallace criteria (9). The state of inactive disease was reached if the 
following four criteria were met for 6 consecutive months (2 consecutive visits), regardless of 
medication intake: (1) no joints with active arthritis, (2) no fever, rash, serositis, splenomegaly 
or generalized lymphadenopathy attributable to JIA, (3) no active uveitis, and (4) PGADA 
indicates no disease activity. The fifth item, normal ESR or CRP, was not included in the 
definition of inactive disease due to the high proportion of missing data and the fact that oligo-
JIA patients often have normal inflammatory markers.  
 
Statistical analysis 
Descriptive statistics were used, as appropriate. Comparisons between patient characteristics, 
based on their IAS exposure status, were done using the chi-square, Fisher's exact, unpaired t 
test or Mann-Whitney U test. Because our outcomes consisted of repeated measurements, we 
used generalized estimating equations (GEE) logistic regression to account for within-patient 
correlation in the data. Models incorporated an M-dependent (m=3) and first-order 
autoregressive working correlation matrix for the primary and secondary outcomes, 
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respectively. We first explored the effect of exposure to early IAS and other important patient 
characteristics on the risk of achieving an active joint count of zero and inactive disease with 
univariate analyses. Variables with a p value <0.10 were considered for the multivariate 
model. Early IAS was forced into the model because this was our covariate of interest. Being 
on NSAIDs at baseline and early exposure to DMARDs were also included as these variables 
were considered clinically relevant. In addition, covariate adjustment for statistical models 
included all empirical confounders for the association between early IAS and the outcome. We 
used a conservative 8% change-in-estimate rule to identify empirical confounders suitable for 
inclusion in the model. The following 7 variables were considered to be potential confounders 
and were tested as described above: oligo-JIA course, active joint count of zero at enrollment, 
early exposure to DMARDs, on NSAIDs at enrollment, baseline CHAQ, PGADA and Patient 
Global. Interaction between exposure to early IAS and time since enrollment was examined. A 
p value < 0.05 for the variable early IAS and the interaction term was considered statistically 
significant in the multivariate model. Multiple imputation was performed for 8 variables with 
missing data: inactive disease (0.2% of missing data), duration of symptoms at diagnosis (2%), 
oligo-JIA course (1%), ANA status (4%), early exposure to DMARDs (8%), on NSAIDs at 
enrollment (7%), baseline CHAQ (19%) and baseline Patient Global (19%). The following 
variables were used as predictors in the imputation model: gender, age at diagnosis, duration 
of symptoms at diagnosis, disease duration at enrollment, higher volume center, oligo-JIA 
course, ANA status, exposure to early IAS, early exposure to DMARDs, on NSAIDs at 
enrollment, baseline CHAQ, baseline PGADA, baseline Patient Global, active joint count of 
zero and inactive disease. The Markov Chain Monte Carlo modelling method was utilized 
(10). The number of iterations was set at 200 and 10 imputed datasets were created. Data 
imputation and analysis was performed using IBM SPSS Statistics Version 21.0. (Armonk, 
NY: IBM Corp.). 
 
Results 
Patient characteristics 
Up to September 11th 2009, 524 oligo-JIA patients had been enrolled into ReACCh Out and 
had their baseline visit entered into the central database. A total of 214 patients were excluded 
from the current study for the following reasons: one or more of the first five study visits were 
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missing (N=181), the first IAS was done before study enrollment (N=22) or no information on 
whether or not IAS was performed was available (N=11). Baseline demographics of these 214 
patients were compared to those of the 310 children included in the study (Table II). Excluded 
patients were older and had milder disease as suggested by a higher proportion of patients 
without active joints and a lower PGADA score at study enrollment.  
 
The study population consisted of 310 children with oligo-JIA, of whom 230 (74.2%) were 
girls. Two hundred forty-nine (81.4%) patients had a persistent oligo-JIA course (course 
unknown in 4 patients). The median (IQR) age at JIA diagnosis was 4.9 (2.3-9.4) years and the 
median (IQR) disease duration at enrollment was 0.7 (0-2.2) months. Three (academic centers) 
of the 16 enrolling centers did not contribute any participants for this study as data from these 
centers had not been entered in the central database at time of data extraction. During the 
study period, 111 (35.8%) patients received an early IAS. Characteristics of patients at study 
entry are shown in Table III. At baseline, important differences between IAS exposure groups 
were a shorter disease duration and a higher active joint count, CHAQ, PGADA and Patient 
Global in the early IAS group. The proportion of patients taking NSAIDs at enrollment was 
higher in the group of patients who did not receive an early IAS.  
 
Treatment received during the study period 
Among the 310 patients, 184 (59.4%) received at least one IAS during follow-up in both 
groups (early IAS or no early IAS) combined (Table III). The majority of participants were 
taking NSAIDs at one point during the study but the proportion was higher in the group who 
did not receive an early IAS. Patients in the early IAS group were less likely to have received 
early DMARD therapy. Less than a third of patients received MTX and the proportion was 
similar between groups. Leflunomide, hydroxychloroquine and sulfasalazine were not 
frequently utilized. Only 4 patients received therapy with a biologic.   
 
Primary outcome: Active joint count of zero 
From the 6-month study visit onward, an active joint count of zero was found in >60% of 
participants at all study time points (Figure 1. a)). At the 24-month visit, 79 (71.2%; 95%CI 
 31 
61.7-79.2%) and 150 (75.4%; 95%CI 68.7-81.1%) of participants had no active joint in the 
early and no early IAS group, respectively.  
 
On univariate analysis, exposure to early IAS had no significant effect on the outcome active 
joint count of zero (Table IV). Three of the seven tested potential confounding variables were 
found to have a confounding effect: active joint count of zero at baseline (10.6% change in 
estimate), baseline CHAQ (8.5%) and baseline PGADA (16.0%). Time since enrollment, 
oligo-JIA course, ANA status, early IAS exposure, the active joint count of zero at enrollment, 
early exposure to DMARDs, on NSAIDs at enrollment, baseline CHAQ and PGADA were 
included in the multivariate model. The final model is shown in Table V. Exposure to early 
IAS, OR 1.52 (95%CI 0.68-3.37; p=0.306), was not statistically significantly associated with 
the outcome active joint count of zero. The direction of the effect was positive i.e. associated 
with an increased risk of reaching an active joint count of zero, which contrasted to what was 
found in univariate analysis. There were no significant interactions between early IAS and 
time since enrollment, OR 0.92 (95%CI 0.85-1.01; p=0.455).  
 
Secondary outcome: Inactive disease 
The number of patients with inactive disease increased at each study visit. Figure 1. b) shows 
the proportion of patients with inactive disease at each time point, depending on their exposure 
status to IAS. The group of patients who did not receive an early IAS was found to have 
inactive disease more frequently during the entire study period. At 24 months, 41 (36.9%; 
95%CI 28.1-46.7%) and 92 (46.2%; 95%CI 39.2-53.4%) participants in the early and no early 
IAS group, respectively, had achieved inactive disease. 
 
Univariate analysis revealed that patients who received an early IAS were significantly less 
likely to achieve inactive disease as compared to those who did not receive an early IAS 
(Table VI). The following two variables were identified as confounders for the association 
between early IAS and inactive disease: active joint count of zero at enrollment (25.4% 
change in estimate) and baseline PGADA (32.2%). Disease duration, time since enrollment, 
oligo-JIA course, ANA status, IAS exposure, on NSAIDs at enrollment, early exposure to 
DMARDs, the active joint count of zero at enrollment, baseline PGADA and baseline CHAQ 
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were included in the multivariate model. The variable Patient Global was not retained for the 
multivariate model because it was highly correlated with baseline CHAQ (Spearman's 
coefficient 0.6; p<0.001). The multivariate model is shown in Table VII. Patients who 
received an early IAS were significantly less likely to achieve inactive disease, OR 0.35 
(95%CI 0.14-0.88; p=0.026). Here again, there were no significant interactions between early 
IAS and time since enrollment, OR 1.21 (95%CI 0.96-1.53; p=0.107).  
 
Discussion 
In this large cohort of Canadian children with oligo-JIA, no significant association was shown 
between early IAS and the achievement of an active joint count of zero in the first two years 
following study enrollment. The OR of early IAS was suggestive of a protective effect on the 
outcome active joint count of zero in multivariate analysis, although the finding was not 
statistically significant.  In contrast, patients who received an early IAS were significantly less 
likely to achieve inactive disease. The discrepancy in the direction of effect of early IAS on 
the primary vs. secondary outcomes was surprising. Inactive disease requires the absence of 
active uveitis thus it is possible that early IAS offers benefit only for the arthritis but not the 
uveitis component of JIA.  
 
No previous studies have addressed the effect of early IAS on disease activity over time in 
oligo-JIA patients. A recently published sub-analysis of the "Behandel Strategieën" (BeSt) 
study compared the disease course over 8 years among 508 early RA (diagnosis <2 years) 
patients who received (N=60) or not (N=448) an IAS within 1 year of study enrollment (11). 
RA patients who were injected had higher Disease Activity Score in 44 joints and Health 
Assessment Questionnaire score during the first year of the study, although the differences 
were less than the minimal clinically significant difference. No significant differences in the 
Disease Activity Score in 44 joints and in the Health Assessment Questionnaire scores were 
found afterwards, up to 8 years after enrollment. Although this study differs in many points 
from our study, it is interesting to note that results were similar to what was found for our 
primary aim i.e. IAS given early on did not seem to impact significantly on the later disease 
course. A retrospective study evaluated the efficacy of multiple IAS performed after a median 
(IQR) of 0.6 (0.2-2.5) years after diagnosis in 220 Italian JIA patients, of whom 109 had oligo-
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JIA (12). Synovitis flare was defined as a flare of arthritis in injected but also in uninjected 
joints. Survival without synovitis flare was 50.0%, 31.5% and 19.5% at 1, 2 and 3 years after 
IAS, respectively. This study had no control group (i.e. systemic therapy without IAS) thus the 
effect of mutiple IAS per se cannot be isolated. Interestingly, the number of joints that flared 
(n=309) was less than half of the number of injected joints (n=725). This may suggest that 
following IAS, less aggressive therapy may be needed to manage disease flares, although the 
absence of a control group precludes definitive conclusions. 
 
The concept of a "window of opportunity" during which one can alter the course of JIA 
remains to be proven. If this window truly exists, it may be that localized, intra-articular 
therapy is not sufficient to alter the disease course. Stronger systemic medications like 
DMARDs or even biologics might be required to achieve this goal. Very few studies have 
addressed the efficacy and impact of more aggressive therapy in recently diagnosed JIA. The 
Aggressive Combination Drug Therapy in Very Early Polyarticular JIA trial was a 
randomized, open label multicentric trial enrolling patients within 6 months of JIA diagnosis 
who were naive to DMARDs (13). Patients were treated with either MTX alone (N=20), 
COMBO therapy (MTX, hydroxychloroquine and sulfasalazine; N=20) and MTX and 
infliximab (N=19). At 54 weeks, inactive disease was achieved by 25%, 40% and 68% of the 
MTX alone, COMBO and MTX-infliximab groups, respectively (p=0.002). Also, the mean 
time spent in inactive disease was longest in the MTX-infliximab arm (26 weeks) when 
compared to the COMBO (13 weeks) and MTX (6 weeks) arms (p=0.001). The TREAT trial 
is another study that relates to the concept of early aggressive therapy in JIA (14). Briefly, 85 
patients with a diagnosis of polyarticular JIA within the last 12 months naive to biologics were 
randomly assigned to either aggressive (MTX, etanercept and prednisolone) or conventional 
(MTX, placebo etanercept and placebo prednisolone) therapy. Patients randomized to the 
aggressive arm were more likely to achieve clinical inactive disease at 6 months (40% vs. 
23%; p=0.08) and clinical remission on medication at 12 months (21% vs. 7%; p=0.05), 
although findings were not statistically significant. No long term data is yet available on the 
outcome of participants of JIA trials who were provided with early aggressive therapy. Only 
then will the concept of a window of opportunity in JIA will be better understood.  
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An encouraging finding was that the proportions of patients that met the primary and 
secondary outcomes were increasing throughout the study duration. On the other hand, at 24 
months, the proportion of patients who still had active joints and who did not achieve inactive 
disease were 26.1% (95%CI 21.4-31.5%) and 57.1% (95%CI 51.4-62.7%) respectively. These 
numbers suggest that there is definitely room for improvement in the oligo-JIA treatment 
scheme. Faster disease control will likely lead to improved physical function and quality of 
life and will possibly prevent the occurrence of damage in these children. 
 
The ReACCh Out cohort contains valuable information on choices of therapeutic agents used 
to treat oligo-JIA. Out of 310 included patients, 184 (59.4%) received at least one IAS during 
the study period. Various rates of IAS have been reported in JIA patients.  Oen et al. studied a 
group of Canadian children diagnosed with JIA between 1974 and 1994, of whom 224 were of 
the oligo-JIA subtype (3). Thirty-two percent had received at least one IAS. Another 
retrospective study of 376 American patients with oligo-JIA diagnosed between 1992-1997 
reported a similar frequency (33%) of IAS use (15). Other authors have reported higher rates 
ranging from 65.8% to as high as >90% (16-18). This wide range might be partly explained by 
the different time periods, locations and duration of follow up of these studies but it also 
reflects the absence of evidence based, formal recommendations on the place of IAS in the 
treatment of JIA. 
 
Strengths and limitations 
This study is the first to address the impact of early IAS on oligo-JIA disease activity over 
time. Because early IAS could have been effective only during the initial stage of the study, 
obtaining multiple data points for the outcome was mandatory to truly appreciate the effect of 
early IAS on disease activity. Missing data is not an uncommon issue in prospective 
multicentric observational studies. Although very few missing data were found for the 
outcome measures, two of the covariates (baseline CHAQ and Patient Global) had both 19% 
of missing data, which led to the exclusion of up to 25% of data if complete case analysis was 
performed. This could have placed a threat on the validity of the study findings. The use of 
multiple imputation is a definite strength as it enabled the use of every included patient and 
minimized the risk of obtaining biased estimates.   
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The absence of a favorable effect of early IAS on the disease course may be due to 
confounding by indication. Early IAS allocation in this study was not randomized but was left 
to the discretion of the treating physician, as this was an observational study. Treatment 
decisions were based on the patients' clinical status and on the physicians' prescribing habits.  
The disease of participants in the early IAS group was more active at study entry, as reflected 
by a higher active joint count, CHAQ and PGADA scores. Hence, it is possible that the patient 
characteristics per se rather than the exposure status to IAS were associated with a worse 
outcome. Confounding by indication is one of the main limitations when estimating treatment 
effect using observational data. We used a conservative 8% change-in-estimate rule to identify 
empirical confounders. It is possible that certain confounders were not adjusted for because 
they were not measured. Multivariate analysis might minimize but may not completely 
eliminate confounding effects. Also, children exposed to an early IAS were less frequently 
prescribed early DMARD therapy and NSAIDs throughout the study. Lack of systemic 
therapy and not necessarily early IAS might explain the apparent worse outcome of these 
children.  
 
Despite the fact that a substantial proportion of enrolled ReACCh Out patients with oligo-JIA 
were excluded from the present analysis, included patients were still representative of the 
typical patients with oligo-JIA, that is young girls with ANA positive persistent oligo-JIA. 
Patients were excluded from this study mainly because they had missed one or more study 
visits. Our inclusion criteria specified that all first five study visits had to be completed. This 
criteria was chosen to ensure we had an adequate number of data points to explore the 
trajectory of outcomes over time. Unfortunately, it might have affected the generalizability of 
the study. We do acknowledge that our findings may not be representative of the overall oligo-
JIA population as we likely selected a subgroup of patients with more active disease at 
baseline. Caution should then be used before generalizing our results to a population of 
patients with milder disease. 
 
Conclusion 
In this study of 310 children with oligo-JIA, no significant association was found between 
early IAS and the achievement of an active joint count of zero during the first two years after 
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study enrollment. Early IAS was associated with a lower risk of achieving inactive disease. 
Methodological issues encountered when estimating treatment effect using observational data 
might have biased the estimates obtained. Firm conclusion on the inefficacy of early IAS in 
improving outcomes of oligo-JIA patients cannot be drawn. Prospective studies addressing the 
limitations raised in this manuscript will be needed to clarify if early IAS can alter the disease 
course over time. 
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Table II.  Baseline demographics of included and excluded patients 
 Included in study 
(N=310) 
Excluded from study 
(N=214) 
p value 
Female / male, N  a 230 / 80 134 / 70 0.038 
Age at diagnosis, years 4.9 (2.4-9.4) 7.3 (3.5-12.3) <0.001 
Duration of symptoms at diagnosis, months 3.6 (2.1-6.1) 4.2 (2.1-9.4) 0.139 
Disease duration, months 0.7 (0-2.2) 1.2 (0-2.9) 0.076 
Higher volume center, N (%) b 180 (58.1) 113 (52.8) 0.233 
Active joint count 1 (1-2) 1 (0-2) 0.015 
Active joint count of zero, N (%) 40 (12.9) 52 (25.0) <0.001 
Baseline PGADA 2.1 (1.0-3.5) 1.3 (0.3-2.9) 0.002 
 
Data presented as median (interquartile range) unless otherwise specified; a N=204 for excluded patients; b Center 
which enrolled ≥ 45 patients; F: female; M: male; PGADA: physician global assessment of disease activity. 
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Table III.  Patient characteristics  
 Early IAS  
(N=111) 
No early IAS 
(N=199) 
p value 
At enrollment    
Female / male, N 86 / 25 144 / 55 0.312 
Age at diagnosis, years  4.5 (2.3-8.4) 5.3 (2.4-9.9) 0.188 
Duration of symptoms at diagnosis, months a 3.6 (2.2-6.0) 3.4 (2.1-6.1) 0.739 
Disease duration, months 0 (0-0.7) 1.2 (0-3.5) <0.001 
Higher volume center, N (%) b 64 (57.7)  116 (58.3) 0.914 
Oligo-JIA course, N (%) c   0.206 
     Persistent 92 (85.2) 157 (79.3)  
     Extended 16 (14.8)  41 (20.7)  
Active joint count 2 (1-3) 1 (1-2) <0.001 
Active joint count of zero, N (%) 0 40 (20.1) <0.001 
ANA positive, N (%) d 78 (73.6) 104 (54.5) 0.001 
Systemic treatment, N (%)    
     NSAIDs e 34 (32.1) 92 (50.8) 0.002 
     Methotrexate f 2 (2.0) 3 (1.7) 0.999 
     Leflunomide g 0 0 - 
     Corticosteroids g 0 1 (0.6) 0.999 
     Hydroxychloroquine g 0 0 - 
     Sulfasalazine g 0 0 - 
     Biologics g 0 0 - 
Baseline CHAQ h 0.37 (0.12-0.75) 0.12 (0-0.62) 0.003 
Baseline PGADA 2.6 (1.7-4.3) 1.5 (0.5-3.2) <0.001 
Baseline Patient Global i 1.2 (0.4-3.4) 0.8 (0-2.6) 0.031 
During the study    
Number of IAS received, N (%)   <0.001 
   None 0 126 (63.3)  
   1 49 (44.1) 38 (19.1)  
   2 26 (23.4) 19 (9.6)  
   ≥3 36 (32.5) 16 (8.0)  
Disease duration at first IAS, months 1.0 (0.4-1.9) 9.0 (4.5-16.5) <0.001 
Systemic treatment received, N (%)    
   NSAIDs j 94 (89.5)  176 (95.7) 0.043 
   Corticosteroids k 0 5 (2.8) 0.164 
   Methotrexate l 25 (24.8) 54 (29.8) 0.362 
   Leflunomide k 0 1 (0.6) 1.000 
   Hydroxychloroquine k 2 (2.0) 1 (0.6) 0.291 
   Sulfasalazine k 1 (1.0) 2 (1.1) 1.000 
   Biologics k 1 (1.0) 3 (1.7) 1.000 
   Early DMARDs m 5 (4.7) 26 (14.4) 0.011 
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Data presented as median (IQR) unless otherwise specified; a N=304, b Center which enrolled ≥ 45 patients; c 
N=306; d N=297; e N=287; f N=279; g N=277; h N=251; i N=250; j N=289; k N=280; l N=282; m N=286; ANA: 
antinuclear antibody; CHAQ: Childhood Health Assessment Questionnaire; DMARDs: disease-modifying 
antirheumatic drugs; F: female; IAS: intra-articular corticosteroid injection; M: male; NSAIDs: nonsteroidal anti-
inflammatory drugs; Oligo-JIA: oligoarticular juvenile idiopathic arthritis; Patient Global: patient global 
assessment of overall well-being; PGADA: physician global assessment of disease activity. 
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Figure 1.  
a) Proportion of patients with an active joint count of zero 
 
 
 
 
 
 
 
 
 
 
 
 
 
 41 
b) Proportion of patients with inactive disease 
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Table IV. Univariate GEE analysis for variables associated with an active joint count of zero 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 6-monthly visits; ANA: antinuclear antibody; CHAQ: Childhood Health Assessment Questionnaire; DMARDs: 
disease-modifying antirheumatic drugs; IAS: intra-articular corticosteroid injection; NSAIDs: nonsteroidal anti-
inflammatory drugs; Oligo-JIA: oligoarticular juvenile idiopathic arthritis; OR (95%CI): odds ratio (95% 
confidence interval); Patient Global: patient global assessment of overall well-being; PGADA: physician global 
assessment of disease activity. 
 
 OR (95%CI) p value 
Gender   
   Male 1.07 (0.73-1.58) 0.713 
   Female 1  
Age at diagnosis, years 1.00 (0.97-1.04) 0.891 
Time from onset of symptoms to diagnosis, months 0.98 (0.96-1.01) 0.167 
Disease duration, months 1.01 (0.94-1.07) 0.878 
Time since enrollment a 1.16 (1.05-1.27) 0.002 
Higher volume center   
   ≥45 patients recruited 1.08 (0.78-1.49) 0.656 
   <45 patients recruited 1  
Oligo-JIA course    
   Extended 0.31 (0.22-0.45) <0.001 
   Persistent 1  
ANA status   
   Positive 0.69 (0.49-0.96) 0.027 
   Negative 1  
IAS exposure   
   Early IAS 0.94 (0.68-1.31) 0.718 
   No early IAS 1  
NSAIDs at enrollment   
   Yes 1.01 (0.72-1.40) 0.973 
   No 1  
Early DMARDs   
   Yes  0.75 (0.45-1.26) 0.281 
   No 1  
Active joint count of zero at enrollment   
   Yes 1.71 (1.02-2.87) 0.042 
   No 1  
Baseline CHAQ 0.68 (0.49-0.96) 0.026 
Baseline PGADA 0.87 (0.81-0.94) 0.001 
Baseline Patient Global  0.95 (0.88-1.02) 0.164 
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Table V. Multivariate GEE analysis for the association between early IAS and an active joint 
count of zero 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 6-monthly visits; ANA: antinuclear antibody; CHAQ: Childhood Health Assessment Questionnaire; DMARDs: 
disease-modifying antirheumatic drugs; IAS: intra-articular corticosteroid injection; NSAIDs: nonsteroidal anti-
inflammatory drugs; Oligo-JIA: oligoarticular juvenile idiopathic arthritis; OR (95%CI): odds ratio (95% 
confidence interval); PGADA: physician global assessment of disease activity. 
 
 
 
 
 
 
 OR (95%CI) p value 
Independent variables   
Time since enrollment a 1.20 (1.06-1.37) 0.004 
Oligo-JIA course    
   Extended 0.31 (0.21-0.45) <0.001 
   Persistent 1  
ANA status   
   Positive 0.78 (0.56-1.10) 0.162 
   Negative 1  
IAS exposure   
   Early IAS 1.52 (0.68-3.37) 0.306 
   No early IAS 1  
NSAIDs at enrollment   
   Yes 0.97 (0.69-1.37) 0.879 
   No 1  
Early DMARDs   
   Yes  1.25 (0.67-2.33) 0.483 
   No 1  
Active joint count of zero at enrollment   
   Yes 1.40 (0.80-2.44) 0.237 
   No 1  
Baseline CHAQ 0.79 (0.55-1.12) 0.182 
Baseline PGADA 0.89 (0.81-0.98) 0.016 
Interaction term   
Early IAS * time since enrollment 0.92 (0.85-1.01) 0.455 
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Table VI. Univariate GEE analysis for variables associated with inactive disease 
 OR (95%CI) p value 
Gender   
   Male 1.17 (0.79-1.72) 0.428 
   Female 1  
Age at diagnosis, years 1.03 (0.99-1.07) 0.161 
Time from onset of symptoms to diagnosis, months 0.98 (0.94-1.01) 0.141 
Disease duration, months 1.07 (1.01-1.14) 0.027 
Time since enrollment a 1.84 (1.66-2.04) <0.001 
Higher volume center   
   ≥45 patients recruited 1.09 (0.78-1.53) 0.605 
   <45 patients recruited 1  
Oligo-JIA course    
   Extended 0.33 (0.19-0.58) <0.001 
   Persistent 1  
ANA status   
   Positive 0.74 (0.53-1.03) 0.078 
   Negative 1  
IAS exposure   
   Early IAS 0.59 (0.42-0.83) 0.003 
   No early IAS 1  
NSAIDs at enrollment   
   Yes 0.92 (0.45-1.40) 0.662 
   No 1  
Early DMARDs   
   Yes 0.80 (0.40-1.22) 0.429 
   No 1  
Active joint count of zero at enrollment   
   Yes 3.15 (1.96-5.07) <0.001 
   No 1  
Baseline CHAQ 0.68 (0.48-0.98) 0.037 
Baseline PGADA 0.73 (0.66-0.81) <0.001 
Baseline Patient Global  0.91 (0.84-1.00) 0.049 
 
a 6-monthly visits; ANA: antinuclear antibody; CHAQ: Childhood Health Assessment Questionnaire; DMARDs: 
disease-modifying antirheumatic drugs; IAS: intra-articular corticosteroid injection; NSAIDs: nonsteroidal anti-
inflammatory drugs; Oligo-JIA: oligoarticular juvenile idiopathic arthritis; OR (95%CI): odds ratio (95% 
confidence interval); Patient Global: patient global assessment of overall well-being; PGADA: physician global 
assessment of disease activity. 
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Table VII. Multivariate GEE analysis for the association between early IAS and inactive 
disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 6-monthly visits; ANA: antinuclear antibody; CHAQ: Childhood Health Assessment Questionnaire; DMARDs: 
disease-modifying antirheumatic drugs; IAS: intra-articular corticosteroid injection; NSAIDs: nonsteroidal anti-
inflammatory drugs; Oligo-JIA: oligoarticular juvenile idiopathic arthritis; OR (95%CI): odds ratio (95% 
confidence interval); PGADA: physician global assessment of disease activity. 
 
 
 
 
 
 
 OR (95%CI) p value 
Independent variables   
Disease duration, months 0.93 (0.85-1.02) 0.138 
Time since enrollment a 1.87 (1.62-2.17) <0.001 
Oligo-JIA course    
   Extended 0.25 (0.13-0.47) <0.001 
   Persistent 1  
ANA status   
   Positive 0.88 (0.58-1.33) 0.537 
   Negative 1  
IAS exposure   
   Early IAS 0.35 (0.14-0.88) 0.026 
   No early IAS 1  
NSAIDs at enrollment   
   Yes 0.76 (0.51-1.13) 0.180 
   No 1  
Early DMARDs   
   Yes 1.52 (0.79-2.94) 0.211 
   No 1  
Active joint count of zero at enrollment   
   Yes 2.16 (1.12-4.20) 0.022 
   No 1  
Baseline CHAQ 0.93 (0.62-1.40) 0.735 
Baseline PGADA 0.73 (0.63-0.83) <0.001 
Interaction term   
Early IAS * time since enrollment 1.21 (0.96-1.53) 0.107 
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4.2 Missing data 
Due to the potential bias induced by certain types of missing data, this topic deserved further 
exploration. Table VIII shows the proportion of missing data for the dependent and 
independent variables. The primary outcome had no missing data. The variable inactive 
disease used for the secondary outcome only had 3 missing items. The proportions of missing 
data for the independent variables were overall low, except for the variables baseline CHAQ 
and baseline Patient Global, which both had 19% of missing data. 
 
 
Table VIII. Frequency of missing data  
 Missing data  
N (%) 
Dependent variables a  
Active joint count of zero 0 
Inactive disease 3 (0.2) 
Independent variables b  
Gender 0 
Age at diagnosis 0 
Duration of symptoms at diagnosis 6 (1.9) 
Disease duration 0 
Higher volume center c 0 
Oligo-JIA course 3 (1.0) 
ANA status 13 (4.2) 
Early IAS 0 
Early DMARDs 24 (7.7) 
NSAIDs at enrollment  23 (7.4) 
Active joint count of zero at enrollment 0 
Baseline CHAQ 59 (19.0) 
Baseline PGADA 0 
Baseline Patient Global 60 (19.4) 
a N= 1240 (310 patients, 4 visits per patients); b N=310 patients; c Center which enrolled ≥45 patients; ANA: 
antinuclear antibody; CHAQ: Childhood Health Assessment Questionnaire; DMARDs: disease-modifying 
antirheumatic drugs; IAS: intra-articular corticosteroid injection; NSAIDs: nonsteroidal anti-inflammatory drugs; 
Oligo-JIA: oligoarticular juvenile idiopathic arthritis; Patient Global: patient global assessment of overall well-
being; PGADA: physician global assessment of disease activity. 
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To explore the missingness mechanism(s), participant characteristics were compared between 
those with and without a complete dataset (Table IX). Gender, the active joint count of zero at 
enrollment and baseline PGADA were significantly different between the 2 groups. These 
findings suggest that participants with a complete dataset had slightly more active disease at 
enrollment than those who had missing variables.  
 !
Table IX. Patient characteristics as per the completeness of their data  
 Complete data 
N=217 
Missing data  
N=93 
 
p value 
Female / male, N 168 / 49 62 / 31 0.047 
Age at diagnosis, years 5.1 (2.6-9.4) 4.0 (2.0-9.8) 0.252 
Duration of symptoms at diagnosis, months 4.0 (2.2-6.5) 3.2 (2.0-5.4) 0.112 
Disease duration, months 0.5 (0-2.0) 1.0 (0-3.3) 0.133 
Higher volume center, N (%) a 121 (55.8) 59 (63.4) 0.209 
Oligo-JIA course, N (%)   0.232 
   Persistent 173 (79.7) 77 (85.6)  
   Extended 44 (20.3) 13 (14.4)  
Active joint count of zero at enrollment, N (%) 15 (6.9) 25 (26.9) <0.001 
ANA positive, N (%) b 129 (59.4) 53 (63.3) 0.286 
Early IAS, N (%) 73 (33.6) 38 (40.9) 0.224 
NSAIDs at enrollment, N (%) c 93 (42.9) 33 (47.1) 0.530 
Early DMARDs, N (%) d 26 (12.0) 5 (7.2) 0.270 
Baseline CHAQ e 0.25 (0-0.62) 0.25 (0-0.56) 0.872 
Baseline PGADA 2.1 (1.1-3.6) 1.7 (0.3-3.3) 0.043 
Baseline Patient Global f 1.0 (0.2-2.7) 0.7 (0.1-3.4) 0.861 
 
Data presented as median (IQR) unless otherwise specified; a Centers which enrolled ≥ 45 patients ; b N=297; c 
N=287; d N=286; e N=251; f N=250; ANA: antinuclear antibody; CHAQ: Childhood Health Assessment 
Questionnaire; DMARDs: disease-modifying antirheumatic drugs; F: female; IAS: intra-articular corticosteroid 
injection; M: male; NSAIDs: nonsteroidal anti-inflammatory drugs; Oligo-JIA: oligoarticular juvenile idiopathic 
arthritis; Patient Global: patient global assessment of overall well-being; PGADA: physician global assessment of 
disease activity. 
 
 
The presence of differences in baseline demographics between participants with and without 
missing data suggested that the missingness mechanism was not MCAR. All 8 variables 
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(inactive disease, duration of symptoms at diagnosis, oligo-JIA course, ANA status, early 
DMARDs, on NSAIDs at enrollment, baseline CHAQ and baseline Patient Global) with 
missing items were assessed for their missingness mechanism. Results are presented in Table 
X. Four of these 8 variables showed a statistically significant association with at least one 
independent variable. This suggested that the missingness pattern for these variables was at 
least that of MAR.  
 52 
Table X. Associations between the missing status of independent variables and variables in the dataset 
 
ANA status missing  
Early DMARDs 
missing 
 
NSAIDs at enrollment 
missing 
 
 OR (95%CI) p value OR (95%CI) p value OR (95%CI) p value 
Female gender 0.77 (0.23-2.59) 0.677 0.83 (0.33-2.09) 0.696 0.78 (0.31-1.97) 0.599 
Age at diagnosis, years 1.02 (0.90-1.17) 0.735 1.00 (0.91-1.11) 0.933 1.02 (0.92-1.12) 0.761 
Duration of symptoms at diagnosis, months 0.99 (0.93-1.05) 0.713 0.91 (0.80-1.04) 0.161 0.92 (0.81-1.04) 0.194 
Disease duration, months 1.07 (0.90-1.28) 0.452 1.37 (1.22-1.54) <0.001 1.38 (1.23-1.56) <0.001 
Higher volume center a 0.84 (0.27-2.55) 0.753 0.49 (0.21-1.14) 0.096 0.53 (0.23-1.25) 0.146 
Extended oligo-JIA course 0 0.997 0.38 (0.09-1.65) 0.195 0.40 (0.09-1.74) 0.221 
Active joint count 0.91 (0.59-1.41) 0.663 0.24 (0.13-0.46) <0.001 0.16 (0.07-0.33) <0.001 
Active joint count of zero at enrollment 1.24 (0.26-5.81) 0.785 14.0 (5.66-34.65) <0.001 15.62 (6.17-39.55) <0.001 
ANA positive - - 0.83 (0.34-2.04) 0.687 0.76 (0.30-1.89) 0.552 
Early IAS 1.13 (0.36-3.53) 0.838 0.45 (0.16-1.23) 0.119 0.47 (0.17-1.32) 0.152 
Early DMARDs 0 0.998 - - - - 
NSAIDs at enrollment 0.85 (0.23-3.07) 0.800 0 0.996 - - 
Baseline CHAQ 1.03 (0.30-3.52) 0.960 1.06 (0.44-2.54) 0.897 1.10 (0.45-2.67) 0.831 
Baseline PGADA 1.10 (0.85-1.43) 0.459 0.57 (0.41-0.81) 0.002 0.52 (0.35-0.76) 0.001 
Baseline Patient Global 1.17 (0.91-1.51) 0.218 0.85 (0.65-1.12) 0.256 0.84 (0.63-1.12) 0.244 
Active joint count of zero 0.82 (0.10-6.65) 0.853 1.64 (0.21-12.78) 0.639 1.56 (0.20-12.21) 0.672 
Inactive disease 1.64 (0.48-5.57) 0.426 3.32 (1.21-9.14) 0.020 3.13 (1.13-8.65) 0.028 
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Table X. Associations between the missing status of independent variables and variables in the dataset (continued) 
 
Baseline CHAQ missing  
Baseline Patient Global 
missing 
 
Oligo-JIA course 
missing 
 
 OR (95%CI) p value OR (95%CI) p value OR (95%CI) p value 
Female gender 0.56 (0.30-1.02) 0.058 0.70 (0.38-1.29) 0.250 e16.88 0.997 
Age at diagnosis, years 0.96 (0.89-1.03) 0.226 0.96 (0.89-1.03) 0.226 1.07 (0.83-1.38) 0.610 
Duration of symptoms at diagnosis 0.96 (0.92-1.01) 0.154 0.98 (0.94-1.02) 0.268 0.83 (0.50-1.40) 0.492 
Disease duration, months 0.98 (0.88-1.10) 0.777 1.00 (0.90-1.11) 0.959 0.25 (0.01-4.99) 0.361 
Higher volume center a 3.48 (1.76-6.86) <0.001 4.05 (2.01-8.14) <0.001 0.36 (0.03-3.99) 0.403 
Extended oligo-JIA course 1.06 (0.51-2.20) 0.875 1.18 (0.58-2.41) 0.645 - - 
Active joint count 0.97 (0.80-1.17) 0.739 0.93 (0.76-1.14) 0.503 1.09 (0.64-1.85) 0.759 
Active joint count of zero at enrollment 2.03 (0.97-4.29) 0.062 1.98 (0.94-4.17) 0.072 0 0.998 
ANA positive 1.52 (0.81-2.85) 0.190 1.42 (0.77-2.64) 0.263 1.27 (0.11-14.13) 0.848 
Early IAS 2.17 (1.22-3.86) 0.008 2.27 (1.28-4.02) 0.005 e17.62 0.995 
Early DMARDs 0.83 (0.30-2.27) 0.716 0.81 (0.30-2.21) 0.679 0 0.998 
NSAIDs at enrollment 1.18 (0.65-2.14) 0.596 1.35 (0.75-2.45) 0.317 0 0.996 
Baseline CHAQ - - 2.28 (0.77-6.77) 0.137 0.12 (0-503.64) 0.615 
Baseline PGADA 0.95 (0.82-1.10) 0.479 0.95 (0.82-1.10) 0.476 1.00 (0.57-1.76) 0.990 
Baseline Patient Global 1.11 (0.78-1.57) 0.563 - - 0.84 (0.26-2.74) 0.767 
Active joint count of zero 0.94 (0.30-2.91) 0.090 0.96 (0.31-2.98) 0.940 e16.64 0.999 
Inactive disease 0.91 (0.51-1.61) 0.743 0.80 (0.45-1.41) 0.437 0.40 (0.04-4.45) 0.456 
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Table X. Associations between the missing status of independent variables and variables in the dataset (continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables for which the OR is 0 or ex have no 95%CI because the computation of the 95%CI was not possible; a Centers which enrolled ≥ 45 patients; ANA: 
antinuclear antibody; CHAQ: Childhood Health Assessment Questionnaire; DMARDs: disease-modifying antirheumatic drugs; F: female; IAS: intra-articular 
corticosteroid injection; M: male; NSAIDs: nonsteroidal anti-inflammatory drugs; Oligo-JIA: oligoarticular juvenile idiopathic arthritis; OR (95%CI): odds 
ratio (95% confidence interval); Patient Global: patient global assessment of overall well-being; PGADA: physician global assessment of disease activity. 
 Duration of symptoms at 
diagnosis missing 
 Inactive disease missing  
 OR (95%CI) p value OR (95%CI) p value 
Female gender 0.35 (0.02-5.58) 0.454 0.17 (0.02-1.90) 0.151 
Age at diagnosis, years 1.08 (0.79-1.48) 0.620 1.02 (0.79-1.34) 0.862 
Duration of symptoms at diagnosis                  -        -         1.08 (1.00-1.16) 0.049 
Disease duration, months 1.12 (0.75-1.68) 0.585 0                      0.945 
Higher volume center a 0                       0.995 0.36 (0.03-3.99) 0.403 
Extended oligo-JIA course 4.45 (0.27-72.17) 0.294 0 0.997 
Active joint count 0.210 (0.02-1.98) 0.173 0.54 (0.14-1.99) 0.352 
Active joint count of zero at enrollment 6.90 (0.42-112.53) 0.175 0 0.998 
ANA positive e16.70 0.996 0.63 (0.04-10.17) 0.745 
Early IAS 0 0.997 0.90 (0.08-9.99) 0.928 
Early DMARDs 8.47 (0.52-138.89) 0.134 0 0.998 
NSAIDs at enrollment e17.08 0.996 0                       0.996 
Baseline CHAQ 0 0.988 0.09 (0-54.64) 0.456 
Baseline PGADA 1.54 (0.86-2.77) 0.147 0.80 (0.40-1.62) 0.541 
Baseline Patient Global 1.01 (0.42-2.43) 0.988 0.45 (0.06-3.24) 0.429 
Active joint count of zero e16.23 0.999 e16.64 0.999 
Inactive disease 0 0.996 - - 
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To explore the association between the completeness of the dataset and the primary or secondary 
outcomes, a univariate GEE model was created using the independent variable "incomplete 
dataset" (at least one independent and/or outcome variable missing vs. complete dataset). No 
statistically significant association was found between the variable "incomplete dataset" for the 
primary outcome, active joint count of zero (incomplete dataset OR 1.15 (0.81-1.63); p=0.428) and 
the secondary outcome, inactive disease (incomplete dataset OR 1.25 (0.88-1.78); p=0.218).  This 
suggested that the primary and secondary outcomes of patients with and without a complete dataset 
was not significantly different. This may suggest that the missingness mechanism is less likely to 
be MNAR but this cannot be confirm or infirm as it relies on unobserved/unmeasured data. 
 
4.3 Exploration to identify potential confounders  
The search for potential confounding variables for the association between early IAS and the 
primary and secondary outcomes was done by comparing the change in the crude OR from the 
adjusted OR in the presence of the potential confounding variable using multivariate GEE. The 
adjusted OR and OR differences are shown in Tables XI and XII. An OR difference of at least 8% 
was considered significant for a confounding effect. As shown in Table XI, 3 of the 7 tested 
variables satisfied the 8% change-in-estimate rule for the primary outcome. Two potential 
confounders were found for the outcome inactive disease (Table XII). 
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Table XI. Potential confounders for the association between early IAS and active joint count of 
zero 
 Adjusted OR (95%CI) of 
early IAS 
OR difference a  
(%) 
Analysis adjusting for the following variables   
   Oligo-JIA course 0.87 (0.62-1.21) 7.4 
   Active joint count of zero at enrollment 1.04 (0.74-1.46) 10.6 
   On NSAIDs at enrollment 0.94 (0.67-1.31) 0 
   Early DMARDs 0.91 (0.65-1.27) 3.2 
   Baseline CHAQ 1.02 (0.73-1.44) 8.5 
   Baseline PGADA 1.09 (0.78-1.52) 16.0 
   Baseline Patient Global 0.96 (0.69-1.34) 2.1 
 
a OR difference ((crude OR-adjusted OR) / crude OR) x 100; crude OR: 0.94; CHAQ: Childhood Health Assessment 
Questionnaire; 95%CI: 95% confidence interval; DMARDs: disease-modifying antirheumatic drugs; IAS: intra-
articular corticosteroid injection; NSAIDs: nonsteroidal anti-inflammatory drugs; Oligo-JIA: oligoarticular juvenile 
idiopathic arthritis; OR: odds ratio; Patient Global: patient global assessment of overall well-being; PGADA: physician 
global assessment of disease activity. 
 
 
Table XII. Potential confounders for the association between early IAS and inactive disease 
 
a OR difference ((crude OR-adjusted OR) / crude OR) x 100; crude OR: 0.59; CHAQ: Childhood Health Assessment 
Questionnaire; 95%CI: 95% confidence interval; DMARDs: disease-modifying antirheumatic drugs; IAS: intra-
articular corticosteroid injection; NSAIDs: nonsteroidal anti-inflammatory drugs; Oligo-JIA: oligoarticular juvenile 
idiopathic arthritis; OR: odds ratio; Patient Global: patient global assessment of overall well-being; PGADA: physician 
global assessment of disease activity. 
 
 
 Adjusted OR (95%CI) of 
early IAS 
OR difference a  
(%) 
Analysis adjusting for the following variables   
   Oligo-JIA course 0.55 (0.39-0.78) 6.8 
   Active joint count of zero at enrollment 0.74 (0.52-1.06) 25.4 
   On NSAIDs at enrollment 0.57 (0.40-0.81) 3.4 
   Early DMARDs 0.57 (0.40-0.81) 3.4 
   Baseline CHAQ 0.62 (0.44-0.89) 5.1 
   Baseline PGADA 0.78 (0.55-1.11) 32.2 
   Baseline Patient Global 0.61 (0.43-0.86) 3.4 
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4.4 Complete case analysis 
When analysis was performed as complete case analysis, similar results were obtained than those 
presented for the imputed dataset for the relationship between early IAS and the primary outcome 
(Tables XIII and XIV). For the secondary outcome inactive disease, the covariate early IAS was 
not statistically significant when included in the multivariate model but the direction of effect 
remained non-protective (Tables XV and XVI).  
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Table XIII. Complete case univariate GEE analysis for variables associated with an active joint 
count of zero 
 OR (95%CI) p value 
Gender   
   Male 1.07 (0.73-1.58) 0.713 
   Female 1  
Age at diagnosis, years 1.00 (0.97-1.04) 0.891 
Time from onset of symptoms to diagnosis, months 0.98 (0.96-1.01) 0.176 
Disease duration, months 1.01 (0.94-1.07) 0.878 
Time since enrollment a 1.16 (1.05-1.27) 0.002 
Higher volume center   
   ≥45 patients recruited 1.08 (0.78-1.49) 0.656 
   <45 patients recruited 1  
Oligo-JIA course    
   Extended 0.31 (0.22-0.45) <0.001 
   Persistent 1  
Active joint count of zero at enrollment   
   Yes 1.71 (1.02-2.87) 0.042 
   No 1  
ANA status   
   Positive 0.69 (0.49-0.97) 0.032 
   Negative 1  
IAS exposure   
   Early IAS 0.94 (0.68-1.31) 0.718 
   No early IAS 1  
NSAIDs at enrollment   
   Yes 0.95 (0.68-1.31) 0.739 
   No 1  
Early DMARDs   
   Yes 0.67 (0.41-1.10) 0.115 
   No 1  
Baseline CHAQ 0.68 (0.49-0.95) 0.022 
Baseline PGADA 0.87 (0.81-0.94) 0.001 
Baseline Patient Global  0.96 (0.89-1.03) 0.292 
 
a 6-monthly visits; ANA: antinuclear antibody; CHAQ: Childhood Health Assessment Questionnaire; DMARDs: 
disease-modifying antirheumatic drugs; IAS: intra-articular corticosteroid injection; NSAIDs: nonsteroidal anti-
inflammatory drugs; Oligo-JIA: oligoarticular juvenile idiopathic arthritis; OR (95%CI): odds ratio (95% confidence 
interval); Patient Global: patient global assessment of overall well-being; PGADA: physician global assessment of 
disease activity. 
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Table XIV. Complete case multivariate GEE analysis for the association between early IAS and an 
active joint count of zero 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 6-monthly visits; ANA: antinuclear antibody; CHAQ: Childhood Health Assessment Questionnaire; DMARDs: 
disease-modifying antirheumatic drugs; IAS: intra-articular corticosteroid injection; NSAIDs: nonsteroidal anti-
inflammatory drugs; Oligo-JIA: oligoarticular juvenile idiopathic arthritis; OR (95%CI): odds ratio (95% confidence 
interval); PGADA: physician global assessment of disease activity. 
 
 
 
 
 
 
 
 OR (95%CI) p value 
Independent variables   
Time since enrollment a 1.28 (1.05-1.48) 0.001 
Oligo-JIA course    
   Extended 0.33 (0.22-0.50) <0.001 
   Persistent 1  
ANA status   
   Positive 0.65 (0.44-0.96) 0.029 
   Negative 1  
IAS exposure   
   Early IAS 2.00 (0.77-5.20) 0.157 
   No early IAS 1  
NSAIDs at enrollment   
   Yes 0.96 (0.65-1.41) 0.821 
   No 1  
Early DMARDs   
   Yes  1.25 (0.63-2.50) 0.521 
   No 1  
Active joint count of zero at enrollment   
   Yes 1.56 (0.63-3.84) 0.337 
   No 1  
Baseline CHAQ 0.75 (0.52-1.07) 0.115 
Baseline PGADA 0.88 (0.79-0.99) 0.034 
Interaction term   
Early IAS * time since enrollment 0.91 (0.71-1.16) 0.457 
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Table XV. Complete case univariate GEE analysis for variables associated with inactive disease 
 OR (95%CI) p value 
Gender   
   Male 1.17 (0.79-1.72) 0.437 
   Female 1  
Age at diagnosis, years 1.03 (0.99-1.07) 0.147 
Time from onset of symptoms to diagnosis, months 0.98 (0.95-1.01) 0.151 
Disease duration, months 1.06 (0.99-1.13) 0.066 
Time since enrollment a 1.84 (1.66-2.05) <0.001 
Higher volume center   
   ≥45 patients recruited 1.10 (0.79-1.53) 0.590 
   <45 patients recruited 1  
Oligo-JIA course    
   Extended 0.33 (0.19-0.58) <0.001 
   Persistent 1  
Active joint count of zero at enrollment   
   Yes 2.75 (1.68-4.50) <0.001 
   No 1  
ANA status   
   Positive 0.74 (0.53-1.04) 0.087 
   Negative 1  
IAS exposure   
   Early IAS 0.59 (0.42-0.83) 0.003 
   No early IAS 1  
NSAIDs at enrollment   
   Yes 0.92 (0.65-1.31) 0.662 
   No 1  
Early DMARDs   
   Yes 0.70 (0.40-1.22) 0.207 
   No 1  
Baseline CHAQ 0.66 (0.45-0.96) 0.031 
Baseline PGADA 0.73 (0.66-0.81) <0.001 
Baseline Patient Global  0.91 (0.83-0.99) 0.033 
 
a 6-monthly visits; ANA: antinuclear antibody; CHAQ: Childhood Health Assessment Questionnaire; DMARDs: 
disease-modifying antirheumatic drugs; IAS: intra-articular corticosteroid injection; NSAIDs: nonsteroidal anti-
inflammatory drugs; Oligo-JIA: oligoarticular juvenile idiopathic arthritis; OR (95%CI): odds ratio (95% confidence 
interval); Patient Global: patient global assessment of overall well-being; PGADA: physician global assessment of 
disease activity. 
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Table XVI. Complete case multivariate GEE analysis for the association between early IAS and 
inactive disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 6-monthly visits; ANA: antinuclear antibody; CHAQ: Childhood Health Assessment Questionnaire; DMARDs: 
disease-modifying antirheumatic drugs; IAS: intra-articular corticosteroid injection; NSAIDs: nonsteroidal anti-
inflammatory drugs; Oligo-JIA: oligoarticular juvenile idiopathic arthritis; OR (95%CI): odds ratio (95% confidence 
interval); PGADA: physician global assessment of disease activity. 
 
 
 
 
 
 OR (95%CI) p value 
Independent variables   
Disease duration, months 0.88 (0.77-1.00) 0.054 
Time since enrollment a 2.16 (1.86-2.51) <0.001 
Oligo-JIA course    
   Extended 0.26 (0.13-0.53) <0.001 
   Persistent 1  
ANA status   
   Positive 0.63 (0.39-1.03) 0.066 
   Negative 1  
IAS exposure   
   Early IAS 0.58 (0.19-1.78) 0.343 
   No early IAS 1  
NSAIDs at enrollment   
   Yes 0.75 (0.45-1.23) 0.257 
   No 1  
Early DMARDs   
   Yes 1.61 (0.74-3.51) 0.234 
   No 1  
Active joint count of zero at enrollment   
   Yes 3.42 (1.27-9.25) 0.015 
   No 1  
Baseline CHAQ 0.87 (0.53-1.42) 0.572 
Baseline PGADA 0.70 (0.60-0.81) <0.001 
Interaction term   
Early IAS * time since enrollment 1.15 (0.87-1.52) 0.321 
  
 
Chapter 5: Discussion 
In this large cohort of Canadian children with oligo-JIA, no significant association was found 
between early IAS and the achievement of an active joint count of zero in the first 2 years 
following study enrollment. The OR of early IAS was suggestive of a protective effect on the 
outcome active joint count of zero in multivariate analysis, although the finding was not 
statistically significant. In contrast, early IAS remained associated with a decreased risk of 
achieving inactive disease, even after adjusting for potential confounders. The discrepancy in 
the direction of effect of early IAS on the primary vs. secondary outcomes was surprising. 
Inactive disease requires the absence of active uveitis thus it is possible that early IAS offers 
benefit only for the arthritis but not the uveitis component of JIA. Overall, our results suggest 
that performing IAS early after oligo-JIA diagnosis offers no clear benefit in terms of 
improving the initial disease course. Early localized injections of corticosteroid may not be 
enough to put the disease in check. If a window of opportunity truly exists in oligo-JIA, 
systemic medications, like DMARDs or biologics, may be needed to favorably alter the 
disease course.  
 
No similar studies completed in a JIA population has addressed the efficacy of early IAS on 
the disease course over time. It is interesting to note that results of the BeSt study were similar 
to our findings for the primary aim i.e. IAS given to RA patients within 2 years after diagnosis 
did not seem to impact significantly on the later disease course (65). We believe that the 
shorter interval (3 months) between disease diagnosis and IAS used in our study was 
preferable. Until the concept of a window of opportunity is better defined, studies aiming to 
explore this theory should err on the side of caution and use narrower time intervals. This 
could lower the risk of making erroneous conclusion resulting from the administration of the 
intervention outside the critical window period. On the other hand, longer follow up time than 
what was done in our study is needed to ascertain if earlier disease control will offer sustained 
benefit. 
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An encouraging finding was that chances to meet the primary and secondary outcomes were 
increasing throughout the study duration. At least 60% of participants had an active joint count 
of zero throughout the study. At 24 months, the proportion of patients with an active joint 
count of zero and inactive disease were 73.9% (95%CI 68.5-78.6%) and 42.9% (95%CI 37.4-
48.6%), respectively. Although the concept of improvement over time is encouraging, these 
numbers suggest that there is definitely room for improvement in the oligo-JIA treatment 
management scheme. Faster disease control will likely lead to improved physical function and 
quality of life and will possibly prevent the occurrence of damage in these children.  
Comparisons with other JIA cohorts are difficult to make as follow up time and definition 
used for inactive disease vary. Most of the other studies distinguished between remission on 
and off medications but our study did not. We used the absence of active joints and inactive 
disease for a minimum of 6 consecutive months regardless of medication intake, as the focus 
was set on having inactive disease. A recently published retrospective study with a median 
(IQR) follow up of 4.3 (2.7-6.1) years reported the rates of inactive disease and remission 
following at least one IAS in 77 children with JIA of whom 64 (83.1%) had oligoarticular 
disease (79). At the last recorded visit, 15 (19.5%) had inactive disease, 3 (3.9%) were in 
remission on medication and 20 (26.0%) were in remission off medication. Taken together, 
49.4% of participants had no active joints at the last study visit, which is lower than what was 
reported in our study. This could be explained by the longer follow up time, allowing time for 
patients to flare, and the higher proportion of patients with oligo-extended JIA and other non-
oligo subtypes included in that study. The Childhood Arthritis Prospective Study (CAPS) 
reported the outcome of 385 oligo-JIA patients followed at 5 tertiary centers in the United 
Kingdom (80). One year after presentation, the median (IQR) active joint count was 0 (0-1) in 
both oligo-persistent and extended JIA patients. The same results were obtain in our oligo-
persistent JIA patients but our oligo-extended group had a higher median (IQR) active joint 
count at the 12-month visit (2 (0-3)). The difference seen in oligo-extended children may be 
partly explained by the higher proportion of patients that received systemic medications or 
IAS in the CAPS cohort. In the Nordic Cohort Study, 87 (69.0%) of 126 oligo-persistent JIA 
were either in remission on or off medications after a median (range) time of 98 (84-147) 
months following disease onset. As expected, the proportion was lower for the oligo-extended 
subgroup with 28 (37.3%) patients in remission on or off medication. These longer term 
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studies reinforce the fact that oligo-JIA must be considered a chronic disease as a significant 
proportion of patients may have active disease many years after onset. The scientific 
community should aggressively pursue the search for better treatment combination that would 
enable more children to become, and most importantly, stay in remission over the long term. 
 
The ReACCh Out cohort allowed to obtain valuable contemporary information on the use of 
IAS in oligo-JIA. Among the 310 participants included in our study, 184 (59.4%) received at 
least one IAS during the first 2 years following study enrollment. Studies have reported a wide 
range of IAS utilization in JIA. Oen et al. retrospectively studied a cohort of Canadian JIA 
patients diagnosed between 1974 et 1994 of whom 224 had an oligoarticular disease course 
(20). After a median (range) follow up duration of 13.5 (5.6-25.8) years, 32% had received at 
least one IAS. Another retrospective study done on 376 American children diagnosed with 
oligo-JIA between 1992-1997 who were followed for at least one year, reported a very similar 
rate of IAS use (33%) (27). Other studies have reported a much higher frequency of IAS. 
More recent data coming from the Childhood Arthritis Rheumatology Research Alliance 
registry informed us on the use of IAS among 2748 JIA patients after a median (IQR) disease 
course of 3.9 (1.8-7.2) years (81). Among the 948 oligo-JIA patients, 65.8% had been given at 
least one IAS. In the CAPS cohort, 75.1% of 385 oligo-JIA patients received an IAS within 
the first year after presentation (80). Guillaume et al. found even a higher proportion in their 
retrospective study of 207 French oligo-JIA patients seen between 1988-1998 (14). Despite a 
relatively short mean follow up time (4.2 ± 2.5 years), >90% of patients had received an IAS.  
This wide range of IAS utilization might be partly explained by the different time periods, 
locations and duration of follow up of these studies. It also reflects the absence of evidence-
based, formal recommendations on the place of IAS in the treatment of JIA. It will be 
interesting to see if, following the American College of Rheumatology recommendations for 
the treatment of JIA published in 2011, in which IAS is part of first-line agent choices, a 
change in the prescription pattern of IAS for children with JIA will be detected. 
 
The use of IAS as a first-line agent is often dictated by its perceived efficacy, the ease with 
which it can be performed, the number of joints involved, the age of the patient and the 
presence of comorbidities (i.e. uveitis). A survey conducted among pediatric rheumatologist 
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across Canada and the United States showed that the majority of physicians thought that IAS 
were more effective than NSAIDs as first-line therapy in children with knee monoarthritis 
(82). Despite their belief in the efficacy of IAS, 63% proposed initial treatment with NSAIDs 
in a fictional scenario involving a 2 year old girl. They proposed IAS as the next therapeutic 
step if the patient was not improving. When the scenario involved an older patient, only an 
additional 11% of physicians changed their initial recommendations and suggested IAS as 
first-line therapy. On the other hand, the presence of local complications such as joint 
contracture or limb length discrepancy led a majority of physicians (64%) to suggest IAS as 
the initial therapeutic step. A survey performed among 127 Canadian and American pediatric 
rheumatologists explored barriers to IAS use in children with JIA (59). The most frequent 
limiting step was the lack of easy access to patient sedation (33%) followed by lack of 
physician's time (22%) and insufficient medical support staff (21%).  
 
The vast majority of participants received NSAIDs at one point during the study. This class of 
medication is the one most commonly used for the systemic treatment of oligo-JIA patients. 
Nearly a third of patients received MTX and a small proportion of participants received 
leflunomide (1/280) and biologics (4/280).  Considering that throughout the study, the highest 
proportion of patients found with inactive disease was only 42.9% (95%CI 37.4-48.6%), one 
may question the low frequency with which DMARDs were prescribed. The definition used to 
consider a patient exposed to a specific medication required a minimum period of intake hence 
it is possible that the proportions were underestimated. Certain physicians may be reluctant to 
start a DMARD or a biologic agent when the child only has 1 or 2 active joints. The use of 
IAS alone or as complementary therapy to NSAIDs is an attractive option for these scenarios. 
The early use of DMARDs in our cohort of oligo-JIA patients resembles that reported in the 
Nordic Cohort Study (18). In the later cohort, 9.3% of oligo-JIA patients were started on 
DMARDs within 7 months of disease onset. Among the 385 oligo-JIA enrolled in the CAPS 
cohort, 329 (85.5%), 89 (23.1%) and 6 (1.6%) had received treatment with NSAIDS, MTX 
and biologics, respectively, one year after presentation (80). The frequencies of DMARDs and 
biologics use were similar to that reported in our study despite the fact that our follow up time 
extended to 2 years. The Childhood Arthritis Rheumatology Research Alliance registry 
reported the use of DMARDs in 587 (61.9%) and of biologics in 247 (26.1%) of 948 enrolled 
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oligo-JIA patients (81). These higher numbers likely reflect the longer disease duration of 
these patients at time of data analysis. It also highlights the fact that oligo-JIA is not a benign 
condition and will not uncommonly need immunosuppressive therapy for adequate disease 
control. 
 
5.1 Strengths 
The ReACCh Out cohort provides valuable contemporary information on JIA patients and 
their outcomes. This study is the first to address the impact of early IAS on oligo-JIA disease 
activity. Studies aiming to identify therapeutic agents that will lead to early disease control are 
extremely valuable as early disease control is most likely a key element in improving patients 
outcome over the long run. The repeated measure design allowed to obtain information on the 
outcome over time and not just at a fixed time point. The visualization of the trajectory of the 
outcome is a definite strength of this study as one can better understand the behavior of oligo-
JIA over time. Also, because early IAS could have been effective only during the initial stage 
of the study, obtaining multiple data points for the outcome was mandatory to truly appreciate 
the effect of early IAS on disease activity. Not surprisingly in this longitudinal study, 
approximately 25% of observations would have been lost if analysis would have been 
performed as complete case analysis. This could have placed a threat on the validity of study 
findings. The missingness mechanism of variables with missing items was thoroughly 
investigated. It was found to be MCAR but also MAR which prompted the use of multiple 
imputation. This is a definite strength in the study as it enabled the use of every included 
patient and minimized the risk of obtaining biased estimates.   
 
5.2 Important methodological considerations and limitations 
5.2.1 Confounding 
The absence of a favorable effect of early IAS on the disease course may be due to 
confounding by indication. Early IAS allocation in this study was not randomized but was left 
to the discretion of the treating physician, as this was an observational study. Treatment 
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decisions were based on patients' clinical status and on physicians' prescribing habits.  
Participants in the early IAS group had more active disease at study entry, as reflected by a 
higher active joint count, CHAQ and PGADA scores. Hence, it is possible that the patient 
characteristics per se rather than the exposure status to IAS were associated with a worse 
outcome (figure).  
 
 
Figure 2. Schematization of confounding 
 
   Exposition    Outcome 
 
 
     Confounding factor 
 
 
Confounding by indication is one of the main limitations when estimating treatment effect 
using observational data. Different methods may be utilized to minimize confounding (83). 
Certain methods need to be implemented in the design of the study such as randomization, 
restriction and matching. Others can be used during the analysis stage such as stratification 
and multivariable analysis. The use of propensity score is another method that can be applied 
(84). For the current study, we used multivariable analysis to adjust for confounding. We 
chose a conservative 8% change-in-estimate rule to identify empirical confounders; this 
threshold was selected to ensure all potential confounding variables would be identified. It is 
possible that certain confounders were not adjusted for because they were not measured. Also, 
multivariable analysis might minimize but may not completely eliminate the confounding 
effect(s). The presence of multiple potential confounders would have made stratification a 
complex process to undertake. Propensity score matching could have been an option but this 
method usually requires a certain degree of planning during the design of the trial to allow for 
an adequate degree of overlap in the baseline covariates. 
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Another potential issue was that children exposed to an early IAS were less likely to be taking 
NSAIDs and were less frequently prescribed early DMARD therapy. Lack of systemic therapy 
and not necessarily early IAS might explain the apparent worse outcome of these children. 
Only a small proportion of patients in both groups were exposed to early DMARDs, it is 
therefore difficult to properly assess the effect of this variable on the outcomes and on the 
relationship between early IAS and the outcomes. Both variables were included in the 
multivariate model as adjustment for these 2 variables was felt to be clinically relevant, 
despite the fact that they did not appear to have a confounding effect. 
 
5.2.2 Difference in disease duration at enrollment 
The ReACCh Out cohort is an inception cohort recruiting participants within one year of their 
JIA diagnosis. Although this may seem to be a relatively narrow time frame, patients may not 
be at the same disease stage when they were enrolled in the study. To illustrate this concept 
better, the following example will be used. Two patients (A and B) take the same number of 
months (i.e. 15 months) to achieve an active joint count of zero. These 2 patients are followed 
for 2 years. Patient A is enrolled at the time of his JIA diagnosis but patient B is enrolled 10 
months after his diagnosis. At the last study visit, patient A has not yet reached an active joint 
count of zero but patient B has. We could falsely conclude that patient A's outcome is less 
favorable than patient B. Both are following the same disease trajectory but are being 
observed at different moments in their disease course.  
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Figure 3. Effect of disease duration at time of study enrollment  
 
Patient A 
    Disease active 
 
 
 
Study enrollment     Assessment of outcome: Active joint count of zero: no 
 
 
Patient B 
      Disease active 
 
 
 
           Study enrollment     Assessment of outcome: Active joint count of zero: yes 
 
 
In our study, disease duration of the early IAS group was shorter, with a median (IQR) of 0 (0-
0.7) months as compared to the group no early IAS, who had a median (IQR) of 1.2 (0-3.5) 
months (p<0.001).  The early IAS group was in an earlier stage of disease but the absolute 
difference was small. It seems unlikely that the apparent better evolution in those who did not 
receive an early IAS would be explained by this phenomenon. The variable disease duration at 
study entry was included in the multivariate model of the secondary aim but not of the primary 
aim, as it was not statistically significant in univariate analysis and 3 other independent 
variables had already been forced into the model. To ensure that this potential bias did not 
impact on results obtained for the primary aim, the multivariate model for the primary 
outcome was re-run adding disease duration at study enrollment as an independent variable. 
The result obtained for early IAS remained similar (OR 1.44 (95%CI 0.64-3.21), p=0.377 for 
the model with disease duration at enrollment vs. OR 1.52 (95%CI 0.68-3.37); p=0.306 for the 
model without disease duration at enrollment). 
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5.2.3 Considerations related to the IAS procedure 
Information on the type and dose of corticosteroid injected were not considered as potential 
explanatory variables. Triamcinolone hexacetonid is recognized as being superior to other 
corticosteroid formulation and doses used are quite standard. It seemed unlikely that these 2 
elements would have had a significant impact on the outcomes. Also, the use of radiological 
guidance was not taken into account as this information was not available in the central 
database. It is possible that the response to corticosteroid injected under radiological guidance 
differs as intra-articular deposition of the medication can be confirmed whereas it can only be 
presumed when injection is performed without guidance. Therefore we are unable to comment 
on the effect of this variable on the outcomes or on the interaction it could have had with early 
IAS.   
 
5.2.4 Missing data 
Missing data is not an uncommon issue in prospective multicentric observational studies. No 
data was missing for the primary outcome and only a small proportion of data was missing for 
the secondary outcome. The proportions of missing data for some of the independent variables 
were significant, leading to the exclusion of up to 25% of the data when complete case 
multivariate analyses were performed. This could have led to loss of power and precision and 
to biased estimates.  
 
Missing data are often categorized as per their missingness mechanism. This classification is 
not just semantic. Specific analysis performed with a dataset containing certain types of 
missing data may lead to biased estimates. The choice of statistical modeling needs to take 
into account the missingness mechanisms. Three main mechanisms are recognized (85). First, 
MCAR. This mechanism applies when data is missing due to reasons unrelated to observed 
and unobserved data. In other words, the probability that the data is missing is not associated 
with any variable in the dataset (outcomes and independent variables). An hypothetical 
example of this type of missing data in our study would be that for a given patient, the 
baseline CHAQ questionnaire was lost hence no result was available. This type of missing 
data is infrequent. When data are MCAR, most simple techniques that deal with missing data 
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should give valid inferences (86). The second type of missing data is referred to as MAR. This 
applies when data is missing for reasons related to the subject's observed data. With MAR 
data, the simple techniques to handle missing data will often lead to biased estimates (85). 
Also, ignoring the missing data mechanism and performing certain statistical procedures, such 
as GEE analysis, may also lead to biased estimates (75). Multiple imputation is a technique 
that can be used in that scenario (87). The last missingness category is MNAR. This entails 
that the data is missing for reasons related to the subject's unobserved data i.e. it depends on a 
variable that has not been measured because it is missing. One of the issue with the later 
category is that we can never be certain that the missingness mechanism is or isn't MNAR as it 
depends on unobserved data. Analysis of MNAR data requires more complex statistical 
procedures (88). When there is a reasonable possibility that the missing data is MNAR, 
sensitivity analysis should be performed to examine the effect of different assumptions (i.e. 
MAR vs. MNAR data) on the conclusions drawn. When there is a minimal amount of missing 
data, the identification of the missingness mechanism and resulting choice of statistical 
procedure may not impact on results significantly. On the other hand, when a large amout of 
data is missing, even the most advanced statistical computations may not be enough to 
compensate for the missing data and may result in invalid estimates.  
 
As shown in the result section, the missingness mechanism for 4 of the 8 variables with 
missing items was likely not MCAR as the probabilities of having missing data were 
significantly associated with at least one observed data. This suggested that the missingness 
pattern for those 4 variables was at least that of MAR. This prompted the use of multiple 
imputation to maximize the use of all available data in the dataset and to reduce the risk of 
obtaining bias estimates (73). This method was likely more efficient in minimizing the 
chances of obtaining misleading results as compared to more simple ways of dealing with 
missing data like the missing indicator method or single imputation using the mean/median 
value. Results obtained for the analysis of the primary aim from the imputed vs. the complete 
case dataset were similar i.e. the association between early IAS and the active joint count of 
zero was protective but not statistically significant. The relationship between early IAS and 
inactive disease was statistically significant with the imputed dataset but not when a complete 
case analysis was performed. The imputed dataset allowed to use information from every 
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participants included in this study which could have led to increased power to detect a 
significant difference. Another possibility was that the use of multiple imputation in our study 
setting led to biased results. Simulation studies have shown that when missingness was 
associated with covariates but independent of the outcome, as seen in our study, using multiple 
imputation may biased results away from the null hypothesis as compared to complete case 
analysis which introduces negligible bias (89).  
 
5.3 Internal validity  
Although we tried to minimize confounding by indication, we were most likely unable to 
eliminate this risk completely, as discussed in section 5.2.1. Therefore, we believe that the 
absence of a significant association between early IAS and improved outcomes in our study 
does not preclude that early IAS could potentially alter the oligo-JIA disease course. Future 
work designed specifically to answer that question and thereby addressing the limitations of 
this study will be needed to draw conclusions on this important topic.  
 
Another bias to consider in our study is a selection bias. If the distribution of exposure to IAS 
and outcome in the included study population did not reflect what was observed in the source 
population, a selection bias might have occurred. We found that the group of excluded 
participants had what seemed to be a milder disease at enrollment. Unfortunately, the IAS 
exposure status and outcome of the excluded participants were not available for analysis. 
Formal comparisons of the exposure and outcome status between enrolled and excluded 
children were not feasible. Therefore, we cannot ascertain if this type if bias is present in our 
study.  
 
Another potential threat to internal validity of a study is an information bias. This bias occurs 
when part of the information gathered on the study participants are incorrect. In our study, the 
collection of data on the primary outcome was not blinded to IAS status. Concern for a 
differential information bias may arise. We believe that the later bias is unlikely to have 
occurred. First, physicians who were assessing the primary and secondary outcomes were not 
aware of our specific study objectives when the original data collection took place. Secondly, 
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a request for chart review was sent for every patient with an initially "missing" outcome, 
regardless of the patient exposure status. The chart review was performed in a blinded fashion 
i.e. by a person who was not aware of the participant's exposure status to IAS.  
 
5.4 Generalizability 
Despite the fact that a substantial proportion of enrolled ReACCh Out patients with oligo-JIA 
were excluded from the present analysis, included patients were still representative of the 
typical patients with oligo-JIA, that is young girls with ANA positive persistent oligo-JIA. 
Patients were excluded from this study mainly because they had missed one or more study 
visits. Our inclusion criteria specified that all first 5 study visits had to be completed. This 
criteria was chosen to ensure we had an adequate number of data points to explore the 
trajectory of outcomes over time. Unfortunately, it might have altered the external validity of 
our study. The group of excluded children seemed to represent a subset of oligo-JIA patients 
with milder disease at enrollment. We do acknowledge that our findings may not be 
representative of the overall oligo-JIA population as we likely selected a subgroup of patients 
with more active disease at baseline. Caution should then be used before generalizing our 
results to a population of patients with milder disease. 
 
 The majority of participants were followed at academic centers and all were under the care of 
rheumatologists. Only 2 out of 13 centers were considered community-based centers. This 
could raise concerns about generalizability of findings as one may infer that patients followed 
at academic centers might be sicker than those followed in the community. The participant 
characteristics did not support this statement; median PGADA and CHAQ at baseline were not 
indicative of highly active disease or major functional impairment (90). Few pediatric 
rheumatologists in Canada are practicing at centers that were not recruiting patients in 
ReACCh Out. The predominance of academic centers reflected Canada's pediatric 
rheumatology reality and is unlikely to have skewed participant's selection toward an 
unrepresentative subgroup of oligo-JIA patients.  
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Finally, it is important to realize that GEE models the population means at each point in time 
and from that a trajectory of averages is derived (91). Results obtained from GEE modeling 
will not necessarily apply to one individual i.e. may not allow to predict one individual's 
trajectory but it will inform on the population's trajectory given specific predictors.  
 
  
 
Chapter 6: Conclusion 
Oligoarticular JIA is one of the most frequent rheumatologic disease encountered in children. 
Despite the prevalence of this autoimmune condition, no evidence-based recommendations are 
available on the optimal use of IAS in oligo-JIA and on the impact of early IAS on disease 
control and future disease trajectory. In this study of 310 children with oligo-JIA, no 
significant association was found between early IAS and the achievement of an active joint 
count of zero over the first 2 years after study enrollment. Participants who received an early 
IAS were less likely to achieve inactive disease. Methodological issues encountered when 
estimating treatment effect using observational data might have biased the estimates obtained. 
Hence, firm conclusion on the inefficacy of early IAS in improving outcomes of oligo-JIA 
patients cannot be drawn. Prospective studies addressing the limitations raised in this 
manuscript will be needed to clarify if early IAS can alter the disease course over time. 
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Annex 2: ReACCh Out follow up form 
Study ID#:          Visit Date:                                        Site ID#:                     REACCH OUT STUDY: FOLLOW-UP FORM   1/6 
      D D M M Y Y Y Y       -    
 
VERSION DATE: 15 July 2011 
REACCHͲOUT–FOLLOWͲUPFORM Subject’slastReACChͲOUTvisit:_____________ 

Typeofvisit:
6month 1year 18month 2year 3year 4year 5year

Diagnosis
Previousdiagnosis:
(fromlaststudyvisit,tobecompletedbyRA)

Systemic
Arthritis+IBD
PolyarthritisRF+ve
PolyarthritisRF–ve
 Oligoarthritis–Persistent
 Oligoarthritis–Extended
 Psoriaticarthritis
 Enthesitisrelatedarthritis
 Undifferentiated


Today’sdiagnosis:


Systemic
Arthritis+IBD
PolyarthritisRF+ve
PolyarthritisRF–ve
 Oligoarthritis–Persistent
 Oligoarthritis–Extended
 Psoriaticarthritis
 Enthesitisrelatedarthritis
 Undifferentiated


InterimHistory
JointPain Yes No 
JointSwelling Yes No 
Limp Yes No 
SymptomaticEnthesitis Yes No 
InflammatoryLowBackPain Yes No 
MorningStiffness Yes No IfYES: >=30mins<30mins
Fever Yes No IfYES: QuotidianpatternOtherpattern
SystemicJIARash Yes No 
Psoriasis Yes No 
AnyOphthalmologyExamduringthelast12months Yes No 
 Ifyes,wasuveitispresentatanyoftheseexams? Yes No IfYES:

Asymptomaticuveitis
Symptomaticuveitis
Complicationsofuveitisatanytime
(cataract/glaucoma/synechia/bandkeratopathy,phisis)
Yes No 
NewOnsetInflammatoryBowelDiseasesincelastvisit Yes No IfYES:
Undifferentiated
Crohn’s
UlcerativeColitis

 
 
 
xi 
Study ID#:          Visit Date:                                        Site ID#:                     REACCH OUT STUDY: FOLLOW-UP FORM   2/6 
      D D M M Y Y Y Y       -    
 
VERSION DATE: 15 July 2011 
School:
(tickbox)
N/A
PreͲschool
JK
SK
Elementary
HighSchool
OtherPostͲSecondary
University
Other:___________
Grade:
(tickbox)
1
2
3
4
5
6
7
8
9
10
11
12

Medications(sincelaststudyvisitortoday)
NSAID
Medicationsinclude,butarenotlimitedto:Acetylsalicylicacid(Aspirin),Arthrotec,Celecoxib,Diclofenac,Flurbiprofen,
Ibuprofen,Indocid,Indomethacin,Ketorolac,Lumiracoxib,Meloxicam,Nabumetone,Naproxen,Piroxicam
OthernonͲlistedNSAID:______________________
YesÎ
No
WasitD/Csincethelaststudyvisitortoday?
YesNo
Didthesubjectexperiencesideeffectsthat
requiredadosechangeordiscontinuationof
medicationtodayorsincethelaststudyvisit?
YesNo
Ifyes,details:_____________________________
DMARD
Medicationsinclude,butarenotlimitedto:Azathioprine,Colchicine,Cyclosporin,Hydroxychloroquine,Intravenous
gammaglobulin(IVIG),Leflunomide,Mercaptopurine(Purinethol,6ͲMercaptopurine,6ͲMP),Mesalamine(5ͲASA),
Methotrexateoral,MethorexateSQ,Minocycline,MycophenolateMofetil,Sulfasalazine(SSZ),Thalidomide
OthernonͲlistedDMARD:______________________
Nameofdrug
Startdate
(ifstartedsincelaststudy
visitortoday)
Stopdate
(ifstoppedsincelast
studyvisitortoday)
YesÎ
No
1.____________________
2.____________________
3.____________________
4.____________________
dd/mmm/yyyy_
dd/mmm/yyyy_
dd/mmm/yyyy_
dd/mmm/yyyy_
dd/mmm/yyyy_
dd/mmm/yyyy_
dd/mmm/yyyy_
dd/mmm/yyyy_
Anysideeffectsthat
requiredadosechangeor
D/Cofmedicationtodayor
sincethelaststudyvisit?

YesNo

Ifyes,details:___________
_______________________
_______________________
Biologics
Medicationsinclude,butarenotlimitedto:Abatacept,Adalimumab(HUMIRA),Anakinra(KINARET),Canakinumab(ILARIS),
Etanercept,Golimumab,Infliximab(REMICADE),Rituximab,Tociluzimab
OthernonͲlistedBiologic:______________________
Dose:_______mg

DoseInterval:dailyqwkq2wk
q4wkq6wkq8wks
q10wksq12wks
variable
Startdate
(Ifstartedtoday,orsincelast
thestudyvisit)
Stopdate
(Ifstoppedtoday,orsincelast
thestudyvisit)

YesÎ
No
1.____________________
dd/mmm/yyyy_ dd/mmm/yyyy_
Anysideeffectsthat
requiredadosechange
orD/Cofmedication
todayorsincethelast
studyvisit?

YesNo

Ifyes,details:__________
_____________________
_____________________
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Dose:_______mg

DoseInterval:dailyqwkq2wk
q4wkq6wkq8wks
q10wksq12wks
variable
Startdate
(Ifstartedtoday,orsincelast
thestudyvisit)
Stopdate
(Ifstoppedtoday,orsincelast
thestudyvisit)
Biologics
(continued)

2.____________________
dd/mmm/yyyy_ dd/mmm/yyyy_
Anysideeffectsthat
requiredadosechange
orD/Cofmedication
todayorsincethelast
studyvisit?

YesNo

Ifyes,details:__________
_____________________
_____________________
Steroids Medicationsinclude,butarenotlimitedto:Dexamethasone,Methylprednisolone(MPpulse),Prednisone,Solumedrol
Nameofdrug
Startdate
(ifstartedsincelaststudy
visitortoday)
Stopdate
(ifstoppedsincelaststudyvisit
ortoday)
YesÎ
No
1.____________________
2.____________________
3.____________________
4.____________________
dd/mmm/yyyy_
dd/mmm/yyyy_
dd/mmm/yyyy_
dd/mmm/yyyy_
dd/mmm/yyyy_
dd/mmm/yyyy_
dd/mmm/yyyy_
dd/mmm/yyyy_
Anysideeffectsthat
requiredadosechangeor
D/Cofmedicationtodayor
sincethelaststudyvisit?

YesNo

Ifyes,details:__________
_____________________
_____________________
TopicalEye
Medication
(atthisvisit)
Corticosteroidsandmydriaticsonly.Medicationsinclude,butarenotlimitedto:Atropine,Brimonidine,Combigan,
Cyclopentolate,Dorzolamide,Fluoromethalone,Homatropine,Lotemax,Maxidex,Mydriacyl,Prednisoneeyedrops,
Rimexolone,Steroideyeointment,Timoptic

YesNo 
Analgesics(nonͲNSAID) YesNo Includes:Acetaminophen,Codeine,Gabapentin,Robaxacet
Antinauseants/antiemetics YesNo Includes:Dimenhydrinate(GRAVOL),Ondansetron
GastricProtectants YesNo Includes:Esomeprazole,Famotidine,Omeprazole,
Pantoprazole,Ranitidine,Sucralfate
Biphosphonates YesNo Includes:Alendronate,Pamidronate,ZoledronicAcid,
Risedronate
OralContraceptives YesNo 
Calcium YesNo 
VitaminD YesNo 
Other
Drugs
(atthisvisit)
Folicorfolinicacidorleukovorin YesNo 
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PhysicalExam
Height:______.____cm  Weight:______.____kg
SystemicRash YesNo  Pleuritis YesNo
Psoriasis YesNo  Peritonitis YesNo
Onycholysis YesNo  GeneralizedLymphadenopathy YesNo
NailPits YesNo  Hepatomegaly YesNo
RheumatoidNodules YesNo  Splenomegaly YesNo
Pericarditis YesNo   
 
RheumatologyExam
Dactylitis YesNo IFYES:Numberofdigitsaffected:____
LeglengthDiscrepancy>=1cm YesNo 
Micrognathiaorasymmetryofthejaw YesNo 
AbnormalModifiedSchober YesNoN/A 
AbnormalChestExpansion YesNoN/A 
 
Physician’sGlobalAssessmentofDiseaseActivity
 
 
 
 
  
. 
 
cm PGA
Not active                         Active 
 
ActiveandLimitedRangeofMovementJoints
Anyactivejoints?YesNo
Activejoint:swelling/effusionor2ofthefollowing:limitedROMor
tendernessorpainfulROM.
AnyjointswithlimitedROM?YesNo

 
VERSION DATE: 15 July 2011 
 
 
 Right side Left side Right side Left side 
 
 
 
 
ͲͲͲͲͲͲͲͲͲͲͲͲͲͲmidfootͲͲͲͲͲͲͲͲͲͲͲͲͲ
ͲͲͲͲͲͲͲͲͲ subtalarͲͲͲͲͲͲͲͲ
ͲͲͲͲͲͲͲͲͲͲͲͲͲͲmidfootͲͲͲͲͲͲͲͲͲͲͲͲͲͲ
ͲͲͲͲͲͲͲͲͲsubtalarͲͲͲͲͲͲͲͲͲ
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Enthesitis
Anysiteswithenthesitis?YesNo
 
Numberofother
nonͲclassicalsites:_____
 
 
Labs(todayormostrecentonesincelaststudyvisit)
Toidentifylabresultsfromtodaythatarepending,checkhere
Test TestPerformed Result Unit Date
Haemoglobin DoneNotDone _________ g/LOther:____
PlateletCount DoneNotDone _________ 109/LOther:____
WBC DoneNotDone _________ 109/LOther:____
dd/mmm/yyyy_
ESR DoneNotDone _________ mm/hrOther:____ _dd/mmm/yyyy_
CRP DoneNotDone _________ mg/LOther:____ _dd/mmm/yyyy_
 
 
Serology(sincelaststudyvisit)
Wereanyofthefollowingserologytestsdone?YesNo
ANA PositiveNegative Date:_dd/mmm/yyyy_
RF PositiveNegative Date:_dd/mmm/yyyy_
B27 PositiveNegative Date:_dd/mmm/yyyy_


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
IntraarticularInjections(sincelaststudyvisitortoday)
YesNoIfyes,fillindetailsbelow.
Joint(s) Date Medication Dosage Unit
_________________
Left
Right _dd/mmm/yyyy
Triamcinolonehexacetonide
Triamcinoloneacetonide
Methylprednisoloneacetate
Other:________
 mg
_________________
Left
Right _dd/mmm/yyyy
Triamcinolonehexacetonide
Triamcinoloneacetonide
Methylprednisoloneacetate
Other:________
 mg
_________________
Left
Right _dd/mmm/yyyy
Triamcinolonehexacetonide
Triamcinoloneacetonide
Methylprednisoloneacetate
Other:________
 mg
_________________
Left
Right _dd/mmm/yyyy
Triamcinolonehexacetonide
Triamcinoloneacetonide
Methylprednisoloneacetate
Other:________
 mg
_________________
Left
Right _dd/mmm/yyyy
Triamcinolonehexacetonide
Triamcinoloneacetonide
Methylprednisoloneacetate
Other:________
 mg

SurgicalProcedures(sincelaststudyvisitortoday)
JointArthroplasty:
YesNo Date:_dd/mmm/yyyy
Joint:
Knee
Hip
Other
Side:
Left
Right
Bilateral
Describeotherjoint:
________________________________
________________________________
________________________________

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REACCHͲOUT–INTERIMVISITFORM  Subject’slastReACChͲOUTvisit:_____________ 
 
ActiveandLimitedRangeofMovementJoints
Anyactivejoints?YesNo
Activejoint:swelling/effusionor2ofthefollowing:limitedROMor
tendernessorpainfulROM.
AnyjointswithlimitedROM?YesNo

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Right side Left side Right side Left side 
 
Enthesitis
Anysiteswithenthesitis?YesNo
 
Numberofother
nonͲclassicalsites:_____
ͲͲͲͲͲͲͲͲͲͲͲͲͲͲmidfootͲͲͲͲͲͲͲͲͲͲͲͲͲ
ͲͲͲͲͲͲͲͲͲ subtalar ͲͲͲͲͲͲͲͲ
ͲͲͲͲͲͲͲͲͲͲͲͲͲͲmidfootͲͲͲͲͲͲͲͲͲͲͲͲͲͲ
ͲͲͲͲͲͲͲͲͲsubtalarͲͲͲͲͲͲͲͲͲ
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Physician’sGlobalAssessmentofDiseaseActivity
 
 
 
 
  
. 
 
     Not active            Active 
   cm PGA
 
 
Labs(todayormostrecentonesincelaststudyvisit)
Toidentifylabresultsfromtodaythatarepending,checkhere
Test TestPerformed Result Unit Date
ESR DoneNotDone _________ mm/hrOther:____ _dd/mmm/yyyy_
CRP DoneNotDone _________ mg/LOther:____ _dd/mmm/yyyy_
 
Medications(sincelaststudyvisitortoday’svisit)
NSAID
Medicationsinclude,butarenotlimitedto:Acetylsalicylicacid(Aspirin),Arthrotec,Celecoxib,Diclofenac,Flurbiprofen,
Ibuprofen,Indocid,Indomethacin,Ketorolac,Lumiracoxib,Meloxicam,Nabumetone,Naproxen,Piroxicam
OthernonͲlistedNSAID:______________________
YesÎ
No
WasitD/Csincethelaststudyvisitortoday?
YesNo
Didthesubjectexperiencesideeffectsthat
requiredadosechangeordiscontinuationof
medicationtodayorsincethelaststudyvisit?
YesNo
Ifyes,details:_____________________________
DMARD
Medicationsinclude,butarenotlimitedto:Azathioprine,Colchicine,Cyclosporin,Hydroxychloroquine,Intravenous
gammaglobulin(IVIG),Leflunomide,Mercaptopurine(Purinethol,6ͲMercaptopurine,6ͲMP),Mesalamine(5ͲASA),
Methotrexateoral,MethorexateSQ,Minocycline,MycophenolateMofetil,Sulfasalazine(SSZ),Thalidomide
OthernonͲlistedDMARD:______________________
Nameofdrug
Startdate
(ifstartedsincelaststudy
visitortoday)
Stopdate
(ifstoppedsincelast
studyvisitortoday)
YesÎ
No
1.____________________
2.____________________
3.____________________
4.____________________
dd/mmm/yyyy_
dd/mmm/yyyy_
dd/mmm/yyyy_
dd/mmm/yyyy_
dd/mmm/yyyy_
dd/mmm/yyyy_
dd/mmm/yyyy_
dd/mmm/yyyy_
Anysideeffectsthat
requiredadosechangeor
D/Cofmedicationtodayor
sincethelaststudyvisit?

YesNo

Ifyes,details:___________
_______________________
_______________________
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Medications(continued)
Biologics
Medicationsinclude,butarenotlimitedto:Abatacept,Adalimumab(HUMIRA),Anakinra(KINARET),Canakinumab(ILARIS),
Etanercept,Golimumab,Infliximab(REMICADE),Rituximab,Tociluzimab
OthernonͲlistedBiologic:______________________
Dose:_______mg

DoseInterval:dailyqwkq2wk
q4wkq6wkq8wks
q10wksq12wks
variable
Startdate
(Ifstartedtoday,orsincelast
thestudyvisit)
Stopdate
(Ifstoppedtoday,orsincelast
thestudyvisit)
1.__________________
dd/mmm/yyyy_ dd/mmm/yyyy_
Anysideeffectsthat
requiredadosechangeor
D/Cofmedicationtoday
orsincethelaststudy
visit?

YesNo

Ifyes,details:__________
_____________________
_____________________
Dose:_______mg

DoseInterval:dailyqwkq2wk
q4wkq6wkq8wks
q10wksq12wks
variable
Startdate
(Ifstartedtoday,orsincelast
thestudyvisit)
Stopdate
(Ifstoppedtoday,orsincelast
thestudyvisit)

YesÎ
No

2.___________________
dd/mmm/yyyy_ dd/mmm/yyyy_
Anysideeffectsthat
requiredadosechangeor
D/Cofmedicationtoday
orsincethelaststudy
visit?

YesNo

Ifyes,details:__________
_____________________
_____________________
Steroids Medicationsinclude,butarenotlimitedto:Dexamethasone,Methylprednisolone(MPpulse),Prednisone,Solumedrol
Nameofdrug
Startdate
(ifstartedsincelaststudy
visitortoday)
Stopdate
(ifstoppedsincelaststudyvisit
ortoday)
YesÎ
No
1.____________________
2.____________________
3.____________________
4.____________________
dd/mmm/yyyy_
dd/mmm/yyyy_
dd/mmm/yyyy_
dd/mmm/yyyy_
dd/mmm/yyyy_
dd/mmm/yyyy_
dd/mmm/yyyy_
dd/mmm/yyyy_
Anysideeffectsthat
requiredadosechangeor
D/Cofmedicationtodayor
sincethelaststudyvisit?

YesNo

Ifyes,details:__________
_____________________
_____________________
TopicalEye
Medication
(atthisvisit)
Corticosteroidsandmydriaticsonly.Medicationsinclude,butarenotlimitedto:Atropine,Brimonidine,Combigan,
Cyclopentolate,Dorzolamide,Fluoromethalone,Homatropine,Lotemax,Maxidex,Mydriacyl,Prednisoneeyedrops,
Rimexolone,Steroideyeointment,Timoptic

YesNo 
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VERSION DATE: 15 JULY 2011 
Analgesics(nonͲNSAID) YesNo Includes:Acetaminophen,Codeine,Gabapentin,Robaxacet
Antinauseants/antiemetics YesNo Includes:Dimenhydrinate(GRAVOL),Ondansetron
GastricProtectants YesNo Includes:Esomeprazole,Famotidine,Omeprazole,
Pantoprazole,Ranitidine,Sucralfate
Biphosphonates YesNo Includes:Alendronate,Pamidronate,ZoledronicAcid,
Risedronate
OralContraceptives YesNo 
Calcium YesNo 
VitaminD YesNo 
Other
Drugs
(atthisvisit)
Folicorfolinicacidorleukovorin YesNo 
 
IntraarticularInjections(sincelaststudyvisitortoday)
YesNoIfyes,fillindetailsbelow.
Joint(s) Date Medication Dosage Unit
_________________
Left
Right _dd/mmm/yyyy
Triamcinolonehexacetonide
Triamcinoloneacetonide
Methylprednisoloneacetate
Other:________
 mg
_________________
Left
Right _dd/mmm/yyyy
Triamcinolonehexacetonide
Triamcinoloneacetonide
Methylprednisoloneacetate
Other:________
 mg
_________________
Left
Right _dd/mmm/yyyy
Triamcinolonehexacetonide
Triamcinoloneacetonide
Methylprednisoloneacetate
Other:________
 mg
_________________
Left
Right _dd/mmm/yyyy
Triamcinolonehexacetonide
Triamcinoloneacetonide
Methylprednisoloneacetate
Other:________
 mg
_________________
Left
Right _dd/mmm/yyyy
Triamcinolonehexacetonide
Triamcinoloneacetonide
Methylprednisoloneacetate
Other:________
 mg

SurgicalProcedures(sincelaststudyvisitortoday)
JointArthroplasty:
YesNo Date:_dd/mmm/yyyy
Joint:
Knee
Hip
Other
Side:
Left
Right
Bilateral
Describeotherjoint:
________________________________
________________________________
________________________________

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Child  Health  Assessment  Questionnaire
Without  ANY
Difficulty
Is  your  child  able  to:
-­  Dress,  including  tying  shoelaces  and  doing  buttons?
-­  Shampoo  his/her  hair?
-­  Remove  socks?
DRESSING  and  GROOMING
With  SOME
Difficulty
With  MUCH
Difficulty
UNABLE
To  DO
Not
Applicable
In  this  section,  we  are  interested  in  learning  how  your  child’s  illness  affects  his/her  ability  to  function  in  daily  life.  Please  feel
free  to  add  any  comments  on  the  extra  page  provided  at  the  end  of  this  questionnaire  package.  In  the  following  questions,  please  
mark  an  X  in  the  box  corresponding  to  the  one  response  which  best  describes  your  child’s  usual  activities  (averaged  over  an  
entire  day)  OVER  THE  PAST  WEEK. ONLY  NOTE  THOSE  DIFFICULTIES  OR  LIMITATIONS  WHICH  ARE  DUE  
TO  ILLNESS.  If  most  children  at  your  child’s  age  are  not  expected  to  do  a  certain  activity,  please  mark  as  “Not  Applicable”.  
For  example,  if  your  child  has  difficulty  in  doing  a  certain  activity  or  is  unable  to  do  it  because  he/she  is  too  young  but  NOT  
because  he/she  is  RESTRICTED  BY  ILLNESS,  please  mark  as  “Not  Applicable”.
-­  Cut  fingernails?
ARISING
Is  your  child  able  to:
-­  Stand  up  from  a  low  chair  or  floor?
-­  Get  in  and  out  of  bed  or  stand  up  in  a  crib?
EATING
Is  your  child  able  to:
-­  Cut  his/her  own  meat?
-­  Lift  a  cup  or  glass  to  mouth?
-­  Open  a  new  cereal  box?
WALKING
Is  your  child  able  to:
-­  Walk  outdoors  on  flat  ground?
-­  Climb  up  five  steps?
Please  mark  any  AIDS  or  DEVICES  that  your  child  usually  uses  for  any  of  the  above  activities:
Please  mark  any  categories  for  which  your  child  usually  needs  help  from  another  person  BECAUSE  OF  ILLNESS:
Dressing  and  Grooming
Cane Walker Crutches Wheelchair Devices  used  for  dressing  
(button  hooks,  zipper  pull,  
long  handled  shoehorn,  etc.)
Built  up  or  
special
utensils
Special  or  
built  up  chair
Other  (specify  below)
Arising Eating Walking
#(!1  
Site  Identification  Number:Study  Identification  Number:
Y Y M M D D-­Y Y
Date:
120 6 18 24
BBOP  Visit Month:
BBOP:
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VERSION DATE: 2007/09/13
Child Health Assessment Questionnaire - continued
Without ANY
Difficulty
Is your child able to:
- Wash and dry entire body?
- Take a tub bath (get in and out of tub)?
- Get on and off toilet or potty chair?
- Brush teeth?
HYGIENE
With SOME
Difficulty
With MUCH
Difficulty
UNABLE
To DO
Not
Applicable
Is your child able to:
- Reach and get down a heavy object such as a large game
  or book from just above his/her head?
- Bend down to pick up clothing or a piece of paper from
  the floor
- Pull on a sweater over his/her head?
- Turn neck to look back over shoulder?
REACH
Is your child able to:
- Write or scribble with pen or pencil?
- Open car doors?
GRIP
- Comb/brush hair?
- Open jars which have been previously opened?
- Turn faucets on and off?
- Push open a door when he/she has to turn a door knob?
Is your child able to:
- Run errands and shop?
- Get in and out of car or toy car or school bus?
ACTIVITIES
- Ride bicycle or tricycle?
- Do household chores (for example, wash dishes, take out 
trash, vacuuming, yardwork, make bed, clean room)?
- Run and play?
 Site Identification Number: Study Identification Number:
Y Y M M D D- -Y Y
 Date:
CHAQ  2/3
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VERSION DATE: 2007/09/13
Child Health Assessment Questionnaire - continued
Please mark any AIDS or DEVICES that your child usually uses for any of the above activities (page 3):
Please mark any categories for which your child usually needs help from another person BECAUSE OF ILLNESS:
Hygiene
Raised toilet seat
We are also interested in learning whether or not your child has been affected by pain because of his or her illness.
  How much pain do you think your child has had because of his or her illness IN THE PAST WEEK?
 Place a mark on the line below to indicate the severity of the pain.
               No pain                     Very severe pain
 
HEALTH STATUS
1.  Considering all the ways that arthritis affects your child, rate how your child is doing on the following scale by placing a 
     mark on the line.
           Very well                          Very poor
 
2.  Is your child stiff in the morning?     Yes            No
 If YES, about how long does the stiffness usually last (in the past week)? 
Completed by:
0 10
cm
0 10
Y Y M M D D- -Y YDate:
cm
Bathtub seat Jar opener (for jars 
previously opened)
Bathtub bar
Longhandled appliance 
for reach
Longhandled appliance 
for bathroom
Reach Gripping and opening things Errands and chores
Parent/Guardian
Patient
Hours Minutes
 Site Identification Number: Study Identification Number:
Y Y M M D D- -Y Y
 Date:
CHAQ  3/3
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